Parameter	Treatment	Baseline	Pulmonary hypertension

			Pre-inhalation

Mw (mWatt·s/ml)	Iloprost	8.29 ± 1.66	10.67 ± 2.45*

	Control	7.54 ± 1.06	9.01 ± 1.27*

Emax (mmHg/ml)	Iloprost	1.10 ± 0.46	1.51 ± 0.74

	Control	1.13 ± 0.62	1.29 ± 0.75

LVEF (%)	Iloprost	61 ± 5	63 ± 12

	Control	57 ± 9	53 ± 7

τ/RR (ms)	Iloprost	0.06 ± 0.02	0.08 ± 0.02

	Control	0.07 ± 0.01	0.07 ± 0.01

β (ml-1)	Iloprost	0.11 ± 0.03	0.11 ± 0.06

	Control	0.11 ± 0.04	0.13 ± 0.09

C (ml/mmHg)	Iloprost	0.72 ± 0.23	0.60 ± 0.20

	Control	0.88 ± 0.27	0.71 ± 0.25*

Ea (mmHg/ml)	Iloprost	1.87 ± 0.51	1.68 ± 0.44

	Control	1.80 ± 0.46	1.93 ± 0.55

Emax/Ea	Iloprost	0.60 ± 0.24	0.92 ± 0.50

	Control	0.62 ± 0.24	0.67 ± 0.31


Characteristics	Patients

8010	8011	8013	8030	8031	8032

Age (years)	50	47	59	69	56	49

Lymphocytosis(×109/L)	6,4	2,5	3,9	2,8	4,4	2,4

Lymphocytosis(% total leukocytosis)	58,4	32,1	36,5	42,5	56,6	48,7

B cells/μL	5250	1550	910	1200	2240	760

Serum IgM(g/L)	12,1	7,8	3,8	9,6	9,5	7,3

Number of BCL-2/Ig rearrangementsa	3 	5 	3 	7 	5 	5

HLA	A 2, 9 B 14, 44Dr 2, 5	A 9, 30 B 13, 14Dr 5, 13	A 9, 39 B 14, 35Dr 5, 13	A 1, 3 B 7, 57Dr 7, 14	ND	A 11, 29 B 35, 44Dr 7, 14

Cigarette smokingb	Yes 	Stopped × 7 years	Yes 	Stopped × 3 years	Yes 	Stopped × 5 years

Characteristics	Patients

8010	8011	8013	8030	8031	8032

B cells/μL	5250	1550	910	1200	2240	760

Serum IgM(g/L)	12,1	7,8	3,8	9,6	9,5	7,3

Number of BCL-2/Ig rearrangementsa	3	5	3	7	5	5

HLA	A 2, 9 B 14, 44Dr 2, 5	A 9, 30 B 13, 14Dr 5, 13	A 9, 39 B 14, 35Dr 5, 13	A 1, 3 B 7, 57Dr 7, 14	ND	A 11, 29 B 35, 44Dr 7, 14

Cigarette smokingb	Yes	Stopped × 7 years	Yes	Stopped × 3 years	Yes	Stopped × 5 years


	Univariate analysis

Factor	Hazard Ratio	p value

Chloroquine treatment	3.28 (1.41-7.63)	0.006

Female	0.93 (0.46-1.91)	0.85

Age (years)	0.96 (0.92-1.00)	0.03

Recruitment site(Jalalabad as reference)

Taloqan	0.79 (0.26-2.43)	0.68

Maimana	3.06 (1.42-6.61)	0.004

Parasitaemia	0.86 (0.32-2.29)	0.76

Presence of gametocytes	1.13 (0.46-2.77)	0.784

Haemoglobin at admission (g/dl)	0.49 (0.37-0.65)	<0.001


Urea mg/dl	37.9 ± 19.0	 ± 13.9	± 23.5	0.33

Mean number of transfused packs of RBC	3.0 ± 2.3	2.2 ± 1.8	3.8 ± 2.6	0.001

Type of heart surgery (CABG/open heart surgery ± CABG)	47/45	26/22	21/23	0.54

Mean extracorporeal circulation time (min.)	112 ± 41.5	108 ± 41.4	115 ± 42	0.37

Postoperative intubation time (hrs) median (IQR [range])	13 (10-18 [4-91])	11 (9-14 [5–29])	18 (14-23[4-91])	<0.001

Time (days) spent in intensive and intermediate care unit, median (IQR [range])	5 (3-6 [2–17])	4 (3-5 [2–15])	6 (5-8 [2–17])	<0.001

Time (hrs) spent in intensive care unit, median (IQR [range])	23 (20-47 [11-289])	21 (19-24 [12-77])	46 (23-78[11-289])	<0.001

Benzodiazepine intake during the night of the sleep study (yes/no)	22 (25.6)	12 (27.9)	10 (25.6)	0.82


MBL	IC50 (μM)

CBS	Bi(NAC)3	Bi(NIT)3	Bi(PCM)2


Classifier	SRCCATT	SRCCAWRST	SRCCAWLT

PCA	1.7 × 10-13	4.7 × 10-12	1.4 × 10-10


Diseases	Genetic variations of TRAFs	References

B cell malignancies

Multiple myeloma	Deletions or inactivating mutations of TRAF3, TRAF2	[294-296]

 	SNPs of TRAF3	[297]

Splenic marginal zone lymphoma	Deletions or inactivating mutations of TRAF3	[298,299]

B cell chronic lymphocytic leukemia	Deletions or inactivating mutations of TRAF3	[298]

Mantle cell lymphoma	Deletions or inactivating mutations of TRAF3	[298]

Waldenström’s macroglobulinemia	Deletions or inactivating mutations of TRAF3	[300]

Hodgkin lymphoma	Deletion of TRAF3	[301]

Diffuse large B-cell lymphoma	Inactivating mutations of TRAF2, TRAF5	[302]

Non-Hodgkin lymphoma	SNPs of TRAF1	[303]

Carcinomas

Breast cancers	Amplification of TRAF4	[304]

Lung cancers	Amplification of TRAF4, TRAF6	[304,305]

Osteosarcoma	Amplification of TRAF6	[306]

Autoimmune diseases

Systemic lupus erythematosus	SNPs of TRAF6, TRAF1/C5	[22,307,308]

Rheumatoid arthritis	SNPs of TRAF5, TRAF6, TRAF1/C5	[22,309-311]

Immunodeficiencies

HSV-1 encephalitis	Inactivating mutation of TRAF3	[312]

Other

Hypohidrotic ectodermal dysplasia	Inactivating mutation of TRAF6	[313]

Diseases	Genetic variations of TRAFs

B cell malignancies

Multiple myeloma	Deletions or inactivating mutations of TRAF3, TRAF2

	SNPs of TRAF3

Splenic marginal zone lymphoma	Deletions or inactivating mutations of TRAF3

B cell chronic lymphocytic leukemia	Deletions or inactivating mutations of TRAF3

Mantle cell lymphoma	Deletions or inactivating mutations of TRAF3

Waldenström’s macroglobulinemia	Deletions or inactivating mutations of TRAF3

Hodgkin lymphoma	Deletion of TRAF3

Diffuse large B-cell lymphoma	Inactivating mutations of TRAF2, TRAF5

Non-Hodgkin lymphoma	SNPs of TRAF1

Carcinomas

Breast cancers	Amplification of TRAF4

Lung cancers	Amplification of TRAF4, TRAF6

Osteosarcoma	Amplification of TRAF6

Autoimmune diseases

Systemic lupus erythematosus	SNPs of TRAF6, TRAF1/C5

Rheumatoid arthritis	SNPs of TRAF5, TRAF6, TRAF1/C5

Immunodeficiencies

HSV-1 encephalitis	Inactivating mutation of TRAF3

Other

Hypohidrotic ectodermal dysplasia	Inactivating mutation of TRAF6


Approach	Pombe	Kinase	Chromosome	ESP	RNA

LLS (K = 20)	0.68	0.85	0.73	0.76	0.77


all

large gene families3

minus large gene families


Category	Variable name	Variable definition

Political Domain	Embassies	Absolute number of in-country embassies and high commissions

	Organizations	Absolute number of memberships in international organizations

	Military	Trade in conventional arms as a share of military spending

Economic domain	Trade	Imports + exports of goods and services as a share of GDP

	FDI	Gross foreign direct stocks as a share of GDP

	Capital	Gross private capital flows as a share of GDP

Social & Cultural Domain	Migrants	Those who changes their country of usual residence per 100 inhabitant

	Tourism	International arrivals + departures per 100 inhabitants

Technological Domain	Phone	Incoming + outgoing international telephone traffic in minutes per capita

	Internet	Internet users as a share of population

Ecological Domain	Eco footprint	Ecological deficit in global ha

Category

Political Domain

Economic domain

Social & Cultural Domain

Technological Domain

Ecological Domain

Variable name	Variable definition

Embassies	Absolute number of in-country embassies and high commissions

Organizations	Absolute number of memberships in international organizations

Military	Trade in conventional arms as a share of military spending

Trade	Imports + exports of goods and services as a share of GDP

FDI	Gross foreign direct stocks as a share of GDP

Capital	Gross private capital flows as a share of GDP

Migrants	Those who changes their country of usual residence per 100 inhabitant

Tourism	International arrivals + departures per 100 inhabitants

Phone	Incoming + outgoing international telephone traffic in minutes per capita

Internet	Internet users as a share of population

Eco footprint	Ecological deficit in global ha


	PfNapL	PfNapS	Vps75	yNAP-1	hSET

Effect binding

1	I136	N112	S95	-	F115

2	I147	K120	S104	K230	R123

No effect on binding to PfNapL	PfNapS	Vps75	yNAP-1	hSET

1*	D192	E161	Q150	D278	S162


Microglia (load (%))	No dementia	Dementia with Alzheimer’s pathology

β	95 % CI (β)	P	β	95 % CI (β)	P

Iba1	0.37	(0.29; 0.45)	<0.001	−0.13	(−0.32; 0.05)	0.154


	Region

	Local group

Group 1	Within-Sichuan group

	Outside-Sichuan group

Group 2


Species	Peptide	Ensembl gene ID	Genome assembly	Comment

Coelacanth	NPY	ENSLACG00000001891	LatCha1

Human	NPY	ENSG00000131096	GRCh37

Coelacanth	PYY	ENSLACG00000015096	LatCha1

Human	PYY	ENSG00000131096	GRCh37

Coelacanth	Pancreatic polypeptide	Not annotated in database (JH126680.1:1,154,715–1,154,819)

Human	Pancreatic polypeptide	ENSG00000108849	GRCh37

Species	Peptide

Coelacanth	NPY

Human	NPY

Coelacanth	PYY

Human	PYY

Coelacanth	Pancreatic polypeptide

Human	Pancreatic polypeptide

Ensembl gene ID	Genome assembly	Comment

ENSLACG00000001891	LatCha1

ENSG00000131096	GRCh37

ENSLACG00000015096	LatCha1

ENSG00000131096	GRCh37

Not annotated in database (JH126680.1:1,154,715–1,154,819)

ENSG00000108849	GRCh37


Database	Type	Species	Method	Entries

Unipep	N-Glycosylated proteins and peptides	Homo sapiens	Hydrazide chemistry & Solid Phase Extraction, in-silico triptic digestion of IPI proteins, and prediction of NXS/T glycosylation site with proteotypic potential	2265

Glycofly	N-Glycosylated proteins and peptides	Drosophila melanogaster	Hydrazide chemistry and Solid Phase Extraction	740

Glycofish	N-Glycosylated proteins and peptides	Danio Rerio	Hydrazide chemistry and Solid Phase Extraction	269

GlycoSuiteDB	O-linked and N-linked Glycoproteins and glycans	 	Published glycoproteins with different methods	9436

GlycoProtDB	N2 and mouse tissues N-Glycoproteins	Caenorhabditis elegans	Lectin Concavilin A Chromatography	1465

Mus Musculus

O-GlycBase NetOGlyc	O and C-Glycosylated proteins	Combination of references	Data curation from literature and coupling ZFN gene targeting, SimpleCell and Lectin Chromatography	2413

3000

dbOGAP	O-GlcNAcylated proteins	Homo Sapiens	Curation from literature and SVM based prediction	798 (exp) 300 (pred)

Mus Musculus

Rattus Norvegicus

Drosophila Melanogaster

Xenopus Laevis

O-GlycBase NetOGlyc	O and C-Glycosylated proteins	Combination of references	Data curation from literature and coupling ZFN gene targeting, SimpleCell and Lectin Chromatography	3000

dbOGAP	O-GlcNAcylated proteins	Homo Sapiens	Curation from literature and SVM based prediction	798 (exp) 300 (pred)

Mus Musculus

Rattus Norvegicus

Drosophila Melanogaster

Xenopus Laevis


Is it possible to reduce the chance of getting the HIV virus by doing the following?	Yes (n = 171; Male)	Yes (n = 231; Female)

n	%	n	%

Always using a condom	161	94	222	96

Having one uninfected sexual partner	150	87	184	79

Clinical male circumcision	138	80	180	77

Abstinence	145	84	210	90


	Dominant model – infection outcome

APOL1 haplotype	T.b.g Disease	T.b.g Carriage	Association analysis*T.b.g Disease/Carriage

	Number	%	Number	%	OR [95% CI]	P

G1 Haplotype†,‡ rs73885319 (A>G) + rs60910145 (T>G)

G1	36	23.4	25	48.1	0.33 [0.17 to 0.64]	0.0012

Non-G1	118	76.6	27	51.9

Total	154	100.0	52	100.0

G2 Haplotype‡ rs71785313 (TTATAA>del6)

G2	50	31.6	4	7.3	5.87 [2.16 to 20.01]	0.0001

Non-G2	108	68.4	51	92.7

Total	158	100.0	55	100.0


Brain regions	MNI coordinate	BA	Clustersize	T-score

	x	y	z

F–NF

 Medial⋅Superior frontal gyrus	3	33	48	8	17	5.23

 Lt. middle temporal gyrus	−66	−39	−6	21	28	5.21

 Lt. middle temporal gyrus	−63	−36	3	22		4.58

 Lt. inferior frontal gyrus/insula	−39	15	9	45/13	17	4.81

	−30	24	6	45		4.64

 Lt. medial frontal gyrus	−3	36	48	8	12	4.60

NF–F

 No significant activation

E–I

 No significant activation

I–E

 Rt. inferior parietal lobule	42	−54	48	40	10	5.02

 Rt. superior parietal lobule	36	−57	54	7		3.87

(I_F–I_NF)–(E_F–E_NF)

 Rt. superior parietal lobule	27	−57	45	7	33	4.74

 Rt. precuneus	24	−72	51	7		3.37

 Lt. fusiform gyrus	−48	−57	−15	37	10	4.22

 Rt. middle frontal gyrus	48	33	18	46	10	3.70

(E_F–E_NF)–(I_F–I_NF)

 No significant activation

Brain regions	MNI coordinate	BA	Clustersize	T-score

	x	y	z

F–NF

Medial⋅Superior frontal gyrus	3	33	48	8	17	5.23

Lt. middle temporal gyrus	−66	−39	−6	21	28	5.21

Lt. middle temporal gyrus	−63	−36	3	22		4.58

Lt. inferior frontal gyrus/insula	−39	15	9	45/13	17	4.81

	−30	24	6	45		4.64

Lt. medial frontal gyrus	−3	36	48	8	12	4.60

NF–F

No significant activation

E–I

No significant activation

I–E

Rt. inferior parietal lobule	42	−54	48	40	10	5.02

Rt. superior parietal lobule	36	−57	54	7		3.87

(I_F–I_NF)–(E_F–E_NF)

Rt. superior parietal lobule	27	−57	45	7	33	4.74

Rt. pr	2	−72

Brain regions	MNI coordinate	BA	Clustersize	T-score

	x	y	z

ecuneus	4		51	7		3.37

Lt. fusiform gyrus	−48	−57	−15	37	10	4.22

Rt. middle frontal gyrus	48	33	18	46	10	3.70

(E_F–E_NF)–(I_F–I_NF)

No significant activation


Amino Acid	mg/g Crude Protein	FAO Report mg/g Protein a	AAS

histidine	38.6 ± 2.3	16	2.41

isoleucine	54.5 ± 0.0	30	1.82

leucine	102.1 ± 0.1	61	1.67

lysine	80.2 ± 5.2	48	1.67

threonine	44.3 ± 3.2	25	1.77

tryptophan	6.0 ± 0.0	6.6	0.91

valine	62.4 ± 2.3	40	1.56

methionine	6.4 ± 0.1	-	-

cysteine	24.1 ± 0.0	-	-

SAA	30.5	23	1.33

tyrosine	31.3 ± 1.3	-	-

phenylalanine	76.9 ± 2.0	-	-

AAA	108.2	41	1.88

aspartic acid	146.1 ± 5.1	-	-

serine	68.5 ± 3.5	-	-

glutamic acid	209.5 ± 4.3	-	-

proline	53.6 ± 1.7	-	-

glycine	46.5 ± 3.4	-	-

alanine	51.4 ± 1.4	-	-

arginine	74.8 ± 6.0	-	-

AAS	0.91	-	-

Limiting amino acid	tryptophan	-	-

Amino Acid	mg/g Crude Protein

histidine	38.6 ± 2.3

isoleucine	54.5 ± 0.0

leucine	102.1 ± 0.1

lysine	80.2 ± 5.2

threonine	44.3 ± 3.2

tryptophan	6.0 ± 0.0

valine	62.4 ± 2.3

methionine	6.4 ± 0.1

cysteine	24.1 ± 0.0

SAA	30.5

tyrosine	31.3 ± 1.3

phenylalanine	76.9 ± 2.0

AAA	108.2

aspartic acid	146.1 ± 5.1

serine	68.5 ± 3.5

glutamic acid	209.5 ± 4.3

proline	53.6 ± 1.7

glycine	46.5 ± 3.4

alanine	51.4 ± 1.4

arginine	74.8 ± 6.0

AAS	0.91

Limiting amino acid	tryptophan


Name	Company	Catalog number	Antibody concentration

DAB2IP	Abcam	ab87811	1 : 1000 or 1 : 200

E-cadherin	Cell Signaling Technology	3195	1 : 500

Vimentin	Cell Signaling Technology	5741	1 : 500

p-ERK1/2	Cell Signaling Technology	4370	1 : 1000

ERK1/2	Cell Signaling Technology	4695	1 : 1000

GAPDH	Beyotime	AG019	1 : 2000

α-tubulin	Sigma-Aldrich	T6199	1 : 2000

Name

DAB2IP

E-cadherin

Vimentin

p-ERK1/2

ERK1/2

GAPDH

α-tubulin

Company	Catalog number	Antibody concentration

Abcam	ab87811	1 : 1000 or 1 : 200

Cell Signaling Technology	3195	1 : 500

Cell Signaling Technology	5741	1 : 500

Cell Signaling Technology	4370	1 : 1000

Cell Signaling Technology	4695	1 : 1000

Beyotime	AG019	1 : 2000

Sigma-Aldrich	T6199	1 : 2000


Intentions *	Male (n)	Female (n)

5	4	3	2	1	5	4	3	2	1	p

After the delivery, I would not try to establish breastfeeding. I would bottle-feed my child with formula milk.	0	1	4	13	25	0	3	5	18	85	/

I would breastfeed my child even if the child’s father does not support my decision to breastfeed.	17	19	5	1	1	67	26	10	6	2	/

I would not breastfeed in public, for example in a restaurant or in a park.	9	11	9	8	6	27	26	29	19	10	/

A child’s mother and father should make a joint decision about breastfeeding.	17	15	7	3	1	11	30	33	20	17	0.000

Returning to work would not make me stop breastfeeding.	9	9	23	1	1	40	38	25	5	3	0.002

I find it acceptable to breastfeed after a child turns one if a child so desires.	9	11	11	9	3	17	30	27	24	13	/

I would breastfeed my child in accordance with doctors’ recommendations, regardless of close family members’ opinions.	19	18	5	0	1	38	42	21	8	2	/

I would not breastfeed my child after he/she turns two.	12	13	13	2	3	44	30	27	6	4	/

Intentions *	Male (n)	Female (n)

5	4	3	2	1	5	4	3	2	1	p

I would breastfeed my child in accordance with doctors’ recommendations, regardless of close family members’ opinions.	19	18	5	0	1	38	42	21	8	2	/

I would not breastfeed my child after he/she turns two.	12	13	13	2	3	44	30	27	6	4	/


	Estimate	Standard Error	Chi-Square (df = 1) or t-value	Odds Ratio	95% Confidence Interval	p-value

W1 drinking predicting stroke	-0.31	0.10	10.8	0.73	0.61–0.88	0.001

W1 drinking predicting heart disease	-0.2	0.08	5.8	0.82	0.69–0.96	0.02

W1 drinking predicting diabetes	-0.30	0.13	5.4	0.74	0.57–0.95	0.02

W1 drinking predicting falls	-0.09	0.06	2.5	0.91	0.81–1.02	0.12

W1 drinking predicting hip fracture	-0.42	0.17	5.8	0.66	0.47–0.92	0.02

W1 Drinking predicting % any ADL	-0.22	0.05	19.9	0.80	0.73–0.88	0.0001

W1 Drinking predicting % any IADL	-0.18	0.04	17.3	0.83	0.77–0.91	0.0001

W1 drinking predicting total # Chronic Illnesses	-0.03	0.01	-2.6	---	---	0.01

W1 drinking predicting CES-D	-0.1	0.03	-3.0	---	---	0.01

W1 drinking predicting TICS-R	0.17	0.08	2.14	---	---	0.03


WNV-L vs. E	CHIKV-L vs. E

Symbol	Entrez gene name	Log2 fold change	P-value	Symbol	Entrez gene name	Log2 fold change	P-value

Lcn2	Lipocalin 2	4.87	6.81E-10	Cxcl10	Chemokine (C-X-C motif) ligand 10	5.09	4.38E-13

Cxcl9	Chemokine (C-X-C motif) ligand 9	4.80	4.46E-11	Lcn2	Lipocalin 2	4.73	4.48E-09

Ubd	Ubiquitin D	4.76	2.59E-17	Ccl5	C-C motif chemokine ligand 5	4.19	4.22E-10

Tnfaip2	TNF alpha induced protein 2	4.71	4.00E-13	Ifi204	Interferon activated gene 204	4.18	5.19E-11

Ccl5	C-C motif chemokine ligand 5	4.43	3.01E-11	Gbp2	Guanylate binding protein 2	4.13	1.34E-13

Gzmb	Granzyme B	4.39	4.20E-15	Lilrb4	Leukocyte immunoglobulin like receptor 4	4.12	5.84E-11

Slfn12l	Schlafen family member 12 like	4.07	1.39E-08	Acod1	Aconitate decarboxylase 1	4.08	6.77E-12

Ifnb1	Interferon beta 1	3.89	9.13E-16	Cxcl9	Chemokine (C-X-C motif) ligand 9	4.02	6.94E-09

Ccl13	C-C motif chemokine ligand 13	3.89	1.92E-13	Ms4a4b	Membrane-spanning 4-domains, subfamily A, member 4B	3.99	3.74E-08

Lilrb4	Leukocyte immunoglobulin like receptor B4	3.89	6.82E-11	Tnfaip2	TNF alpha induced protein 2	3.89	1.48E-10

WNV-L vs. E	CHIKV-L vs. E

Symbol	Entrez gene name	Log2 fold change	P-value	Symbol	Entrez gene name

Lcn2	Lipocalin 2	4.87	6.81E-10	Cxcl10	Chemokine (C-X-C motif) ligand 10

Cxcl9	Chemokine (C-X-C motif) ligand 9	4.80	4.46E-11	Lcn2	Lipocalin 2

Ubd	Ubiquitin D	4.76	2.59E-17	Ccl5	C-C motif chemokine ligand 5

Tnfaip2	TNF alpha induced protein 2	4.71	4.00E-13	Ifi204	Interferon activated gene 204

Ccl5	C-C motif chemokine ligand 5	4.43	3.01E-11	Gbp2	Guanylate binding protein 2

Gzmb	Granzyme B	4.39	4.20E-15	Lilrb4	Leukocyte immunoglobulin like receptor 4

Slfn12l	Schlafen family member 12 like	4.07	1.39E-08	Acod1	Aconitate decarboxylase 1

Ifnb1	Interferon beta 1	3.89	9.13E-16	Cxcl9	Chemokine (C-X-C motif) ligand 9

Ccl13	C-C motif chemokine ligand 13	3.89	1.92E-13	Ms4a4b	Membrane-spanning 4-domains, subfamily A, member 4B

Lilrb4	Leukocyte immunoglobulin like receptor B4	3.89	6.82E-11	Tnfaip2	TNF alpha induced protein 2


	Pol subtype

Env subtype	A	B	C	D	F	G	H	01_AE	02_AG	UA

A-like	59			3	1	3		1	71	16

B	3	1				4			2	2

C	1		62					1

D				5					1

F					6

G	1					12			5	5

H							1

CRF01AE								57

UA						2			2	8


	Range	Mean (SD)

Temperature, centigrade	36–38	37 ± 0.5

Systolic blood pressure, mmHg	100–190	140 ± 24

Diastolic blood pressure, mmHg	60–140	86 ± 22

Heart rate	66–100	84 ± 11

Respiratory rate	14–26	18 ± 3


Variables	HOMA-IR quartiles

Q1

(<1.13)

Age (years)	10.3 ± 1.9

Body composition

BMI (kg/m2)	17.3 ± 2.6

Body fat (%)	7.9 ± 6.5

WC (cm)	62.5 ± 10.2

Blood pressure

SBP (mmHg)	104.2 ± 14.8

DBP (mmHg)	63.8 ± 11.0

Metabolic profiles

TG (mg/dL)	70.0 ± 29.9

TC (mg/dL)	169.3 ± 29.5

HDL-C (mg/dL)	61.3 ± 13.5

Glucose (mg/dL)	86.2 ± 8.2

Insulin (μU/mL)	3.8 ± 1.1


Peg	Coupled Score	Abstract Coupling Score	Function

fig|243277.1.peg.316	6	0.38	Translation elongation factor Tu

fig|243277.1.peg.318	39	0.65	Transcription antitermination protein NusG

fig|243277.1.peg.319	24	0.61	LSU ribosomal protein L11p (L12e)

fig|243277.1.peg.320	36	0.64	LSU ribosomal protein L1p (L10Ae)

fig|243277.1.peg.321	11	0.58	LSU ribosomal protein L10p (P0)

fig|243277.1.peg.322	25	0.67	LSU ribosomal protein L7/L12 (L23e)

fig|243277.1.peg.324	34	0.64	DNA-directed RNA polymerase beta' subunit

fig|243277.1.peg.354	-1	0.42	SSU ribosomal protein S12p (S23e)

fig|243277.1.peg.355	-	0.5	SSU ribosomal protein S7p (S5e)

fig|243277.1.peg.4033	-	0.35	Preprotein translocase subunit SecE

fig|243277.1.peg.356	-	0.27	Translation elongation factor G

Peg	Coupled Score	Abstract Coupling Score	Function

fig|243277.1.peg.318	39	0.65	Transcription antitermination protein NusG

fig|243277.1.peg.319	24	0.61	LSU ribosomal protein L11p (L12e)

fig|243277.1.peg.320	36	0.64	LSU ribosomal protein L1p (L10Ae)

fig|243277.1.peg.321	11	0.58	LSU ribosomal protein L10p (P0)

fig|243277.1.peg.322	25	0.67	LSU ribosomal protein L7/L12 (L23e)

fig|243277.1.peg.324	34	0.64	DNA-directed RNA polymerase beta' subunit

fig|243277.1.peg.354	-1	0.42	SSU ribosomal protein S12p (S23e)

fig|243277.1.peg.355	-	0.5	SSU ribosomal protein S7p (S5e)

fig|243277.1.peg.4033	-	0.35	Preprotein translocase subunit SecE

fig|243277.1.peg.356	-	0.27	Translation elongation factor G


Component score	SOFA	MOD

Cardiovascular	56%	18%

Respiratory	43%	23%

Coagulation	6%	4%

Renal	0.5%	0.5%

Hepatic	1%	0%


	Full study population	Nested case-control samples for different case-control ratios

	DVT +	DVT-	Cases	Controls

Test results	n = 289	n = 1006	n = 289	1:1n = 289	1:2n = 578	1:3n = 867	1:4n = 1156

Male gender	137 (47)	330 (33)	137 (47)	94 (33)	190 (33)	282 (33)	380 (33)


Plan	Plane	6 MV Gamma Passing Rate (%)	Plane	18 MV Gamma Passing Rate (%)

I1 Multitarget	Isocenter	93.9	Isocenter	95.9

I2 Mock Prostate	Isocenter	91.7	Isocenter	91.9

I3 Mock H&N	Isocenter	94.0	Isocenter	95.0

I4 Easy C‐Shape	Isocenter	95.5	Isocenter	89.3

	6 MV Mean	93.8	18 MV Mean	93.3

	6 MV SD	1.6	18 MV SD	3.0

	6 MV CL	9.3	18 MV CL	12.9

	Overall (6 & 18 MV) Mean	93.4

	Overall Standard Deviation	2.3

	Overall Confidence Limit	11.0

Plane	6 MV Gamma Passing Rate (%)	Plane	18 MV Gamma Passing Rate (%)

Overall Standard Deviation	2.3

Overall Confidence Limit	11.0


Transcription factor family	L1 vs. L2 (transcript) Up-or down-regulated	L1 vs. L3 (transcript) Up-or down-regulated

	Up	Down	Up

AP2	1	13	14

ARF	12	11	15

ARR

B-ARR	12	12	9

A-ARR	11	1	10

AUX/IAA	6	38	3

B3	4	1	3

bHLH	13	20	11

bZIP	3	7	1

BEE	0	3	0

Zinc finger

C2H2-type	3	11	5

C3HC4-type	7	6	7

CCCH-type	3	5	4

B-box-type	1	4	4

C3H4 type	2	10	2

CAMTA	15	5	15

ERF	17	30	15

GATA	0	9	1

GRAS	5	13	8

MADS	2	5	5

MYB	18	27	16

HSP	3	10	6

NAC	16	21	9

NF-YA	3	1	4

NF-YB	0	4	1

R2R3-MYB	0	8	0

SPL	4	1	4

TCP	4	10	1

TGA	1	3	1

WRKY	8	28	9


RDQ Scale	Effect size	Standardized response mean

	Esomeprazole	Placebo	Esomeprazole	Placebo

Heartburn	2.05	0.85	1.52	0.74

Regurgitation	1.36	0.63	1.31	0.60

Dyspepsia	1.05	0.56	0.99	0.57

GERDa	2.13	0.93	1.68	0.79

RDQ Scale	Effect size	Standardized response mean

	Esomeprazole	Placebo	Esomeprazole	Placebo

Regurgitation	1.36	0.63	1.31	0.60

Dyspepsia	1.05	0.56	0.99	0.57

GERDa	2.13	0.93	1.68	0.79


Subtypes of epilepsy	T. gondiin (%)	Pvalue	Toxocaran (%)	Pvalue

Idiopathic	16/117 (13.67)	0.8	25/117(21.36)	0.2

Febrile seizure(Special syndrome)	2/10 (20)	0/10(0)

Generalized	2/14 (14.28)	3/14 (21.42)

Subtypes of epilepsy

Idiopathic

Febrile seizure(Special syndrome)

Generalized


Anamnestic and clinicalFeatures of red flags	Sign and symptoms ofSpecific shoulder pain

Fever, shivering, changes in body temperature overnight, diaphoresis, nausea, unexplainable sweating overnight, vomiting, sphincteric complaints, diarrhoea, paleness, fatigue, lurching, fainting, exhaustion, excessive and unexplainable weakness, not linked to any physical effort, unexplainable loss of weight, skin rash, unexplainable multiple hematoma, lumps over the body, deformities, inability to lay supine in bed, marked muscle weakness, marked restriction of movement, limb atrophy, local pain and pain during load when age is less than 20 years old and more than 50.	Recent trauma of the shoulder complex, high reactivity of symptoms, pain during the night, limitation of flexion (< 90° both passive and active), apprehension, fear of movement and/or weakness during humeral external rotation.


	ρ	ρ-partial

Baseline disability	0.46‡

Age	0.26‡	0.28‡

Somatization	0.40‡	0.23‡

Depression	0.35‡	0.25‡

Time since onset of pain	0.14†	0.13†

Coping resources	−0.15†	−0.12*

Resilience	−0.21‡	−0.18‡

Gender	0.02	0.08

Baseline disability

Age

Somatization

Depression

Time since onset of pain

Coping resources

Resilience

Gender


 	Primary Rd until progression (n=9)	Primary Rd stopped before progression (n=11)	Primary Rd stopped with progression and restarted (n=5)	Rd induction followed by SCT (n=8)

Age, years, median (range)	65 (36–70)	60 (40–78)	55 (32–75)	62 (36–73)

Prior plasma cell disorder, N	6 (3 MGUS/SMM; 3 plasmacytoma)	3 (3 MGUS/SMM)	3 (2 MGUS/SMM; 1 plasmacytoma)	3 (1 MGUS/SMM; 2 plasmacytoma)

MDE at presentation	Bone, 8Anemia, 1	Bone, 10Anemia, 1	Bone, 3Anemia, 1Hypercalcemia, 1	Bone, 7Anemia, 1

Molecular classification, N	Trisomies, 5t(11;14) 1t(11;14) plus trisomy, 1Isolated del 13, 1Normal/insufficient, 1	Trisomies, 6t(11;14), 1Not done, 4	Trisomies, 3Normal/insufficient, 1Not done, 1	Trisomies, 4Isolated del 13, 2Normal/insufficient, 2

Best response to therapy	CR, 7VGPR, 2	CR, 9VGPR, 1 PR, 1	CR, 2VGPR, 2 PR, 1	CR, 7PR, 1


Input	Membership Function

RSSI Level	Weak	Medium	Strong

Number of Neighbours	Low	Medium	High

Distance to each neighbour	Near	Medium	Far


Characteristic (N = 148)	Number	Percent

Gender

 Female	126	85.1

Grade level

 Freshman	36	24.3

 Sophomore	38	25.7

 Junior	39	26.4

 Senior	35	23.6

Experience of dementia education

 Yes	63	42.6

Average time of Experienced education (n = 63)

 Less than 2 h	35	55.6

 More than 2 h	28	44.4

Family member with dementia

 Yes	24	16.2

Experience in caring for persons with dementia

 Yes	63	42.6

Cared for people with dementia during clinical placement

 Yes	62	41.9

Exposure to information on dementia

 Yes	111	75.0

Information sourcesa (n = 111)

 Broadcasting	64	43.2

Educational resources	64	43.2

 Internet	40	27.0

 Family/relatives	24	16.2

 Newspaper	21	14.2

 Magazine	2	1.4

 Others	10	6.8

Characteristic (N = 148)	Number	Percent

Newspaper	21	14.2

Magazine	2	1.4

Others	10	6.8


Scale	Factor	N	%

SCL-90-R	Without psychopathology > 0.99	62	44.6

	Somatization (SOM) > 0.99	47	33.8

	Obsessive-compulsive (OC) > 0.99	43	30.9

	Interpersonal sensitivity (IS) > 0.99	19	13.7

	Depression (DEP) > 0.99	50	36.0

	Anxiety (ANX) > 0.99	33	23.7

	Hostility (HOS) > 0.99	28	20.1

	Phobic anxiety (PHO) > 0.99	18	12.9

	Paranoid ideation (PAR) > 0.99	23	16.5

	Psychoticism (PSY) > 0.99	7	5.0

MQ	Vital exhaustion > 18	71	51.1

Scale	Factor	N	%

	Somatization (SOM) > 0.99	47	33.8

	Obsessive-compulsive (OC) > 0.99	43	30.9

	Interpersonal sensitivity (IS) > 0.99	19	13.7

	Depression (DEP) > 0.99	50	36.0

	Anxiety (ANX) > 0.99	33	23.7

	Hostility (HOS) > 0.99	28	20.1

	Phobic anxiety (PHO) > 0.99	18	12.9

	Paranoid ideation (PAR) > 0.99	23	16.5

	Psychoticism (PSY) > 0.99	7	5.0

MQ	Vital exhaustion > 18	71	51.1


Clade	Combined-data and mtDNA	Combined-data and nucDNA	mtDNA and nucDNA

Balistid fish	16%	24%	11%

Scarine fish	83%	63%	50%

Hemiphractid frogs	64%	52%	30%

Hylid frogs	27%	44%	13%

Plethodon salamanders	73%	27%	23%

Phrynosomatid lizards	37%	71%	26%

Alcid birds	91%	33%	23%

Caprimulgid birds	53%	82%	38%

Cotingid birds	53%	71%	35%

Dicaeid birds	80%	34%	24%

Emydid turtles	54%	60%	37%

Cervid mammals	99%	37%	27%

Murid rodents (Philippines)	30%	63%	23%

Murid rodents (Sahul)	55%	96%	53%

Clade	Combined-data and mtDNA	Combined-data and nucDNA	mtDNA and nucDNA

Balistid fish	16%	24%	11%

Scarine fish	83%	63%	50%

Hemiphractid frogs	64%	52%	30%

Hylid frogs	27%	44%	13%

Plethodon salamanders	73%	27%	23%

Phrynosomatid lizards	37%	71%	26%

Alcid birds	91%	33%	23%

Caprimulgid birds	53%	82%	38%

Cotingid birds	53%	71%	35%

Dicaeid birds	80%	34%	24%

Emydid turtles	54%	60%	37%

Cervid mammals	99%	37%	27%

Murid rodents (Philippines)	30%	63%	23%

Murid r			53%

Clade	Combined-data and mtDNA	Combined-data and nucDNA	mtDNA and nucDNA

odents (Sahul)	55%	96%


Human region	Avian region	Reference

Nucleus accumbens (nAc)	Nucleus accumbens (nAc)	Balint and Csillag (2007), Husband and Shimizu (2011)

Ventral tegmental area (VTA)	Ventral tegmental area (VTA)	Bottjer (1993), Reiner et al. (1994)

Caudate nucleus	Lateral striatum (LSt)	Karten (1969), Reiner et al. (1998)

Hippocampus (Hp)	Hippocampus (Hp)	Erichsen et al. (1991)

Medial amygdala (MeA)	Nucleus taeniae of the amygdala (TnA)	Cheng et al. (1999), Reiner and Karten (1985)

Prefrontal cortex (PFC)	Caudolateral nidopallium (NCL)	Mogensen and Divac (1982), Waldmann and Güntürkün (1993)

Human region	Avian region	Reference

Nucleus accumbens (nAc)	Nucleus accumbens (nAc)	Balint and Csillag (2007), Husband and Shimizu (2011)

Ventral tegmental area (VTA)	Ventral tegmental area (VTA)	Bottjer (1993), Reiner et al. (1994)

Caudate nucleu	La	K

Human region	Avian region	Reference

s	teral striatum (LSt)	arten (1969), Reiner et al. (1998)

Hippocampus (Hp)	Hippocampus (Hp)	Erichsen et al. (1991)

Medial amygdala (MeA)	Nucleus taeniae of the amygdala (TnA)	Cheng et al. (1999), Reiner and Karten (1985)

Prefrontal cortex (PFC)	Caudolateral nidopallium (NCL)	Mogensen and Divac (1982), Waldmann and Güntürkün (1993)


	2007	2012

		Exposed to the intervention

		Never	Once	Twice or more	Total	p*	P**

(n = 210)	(n = 63)	(n = 180)

Knowledge of HIV prevention methods	38.8%	59.0%	71.4%	79.4%	68.6%	<10−3	<10−3

Condom use during the most recent sexual encounter with a sex worker	35.5%	40.5%	68.3%	78.5%	60.3%	<10−3	0.34

Systematic condom use with a sex worker in the previous 12 months	12.8%	10.5%	19.0	35.0	21.4%	<10−3	0.38

Voluntary HIV testing and counselling in the previous 12 months	4.3%	6.7%	27.0%	57.8%	29.6%	<10−3	0.20

Knowledge of non-AIDS STI symptoms (men)	24.6%	25.7%	31.7%	36.7%	30.7%	0.02	0.75

Knowledge of non-AIDS STI symptoms (women)	13.4%	9.5%	14.3%	20.0%	14.2%	0.03	0.15

Knowledge that the results of HIV test would remain confidential	23.3%	75.1%	83.9%	92.2%	83.2%	<10−3	<10−3

	2007

Knowledge of HIV prevention methods	38.8%

Condom use during the most recent sexual encounter with a sex worker	35.5%

Systematic condom use with a sex worker in the previous 12 months	12.8%

Voluntary HIV testing and counselling in the previous 12 months	4.3%

Knowledge of non-AIDS STI symptoms (men)	24.6%

Knowledge of non-AIDS STI symptoms (women)	13.4%

Knowledge that the results of HIV test would remain confidential	23.3%


	Mortality 2003	Mortality 2010	Unadjusted HR	Adjusted HR *	Adjusted HR †

	N/total (%)	N/total (%)	(95% CI)	(95% CI)	(95% CI)


Study	Type of study	No. of patients receiving short-term radiotherapy (%)	Experimental group^No of DR/No of patients(%)	Control groupNo of DR/No of patients (%)	P value

Nowacki et al. (2004) [4]	Randomized	78 (40.4)	10/97(10.3)	27/96(28.1)	0.002

Collin et al. (2012) [19]	Randomized	54 (100.0)	9/26(34.6)	14/28(50.0)	0.467

Present study	Randomized	162 (100.0)	9/81(11.1)	21/81(25.9)	0.026

Total	–	294 (72.9)	28/204(13.7)	60/205(29.3)	< 0.001

Study	Type of study	No. of patients receiving short-term radiotherapy (%)	Experimental group^No of DR/No of patients(%)	Control groupNo of DR/No of patients (%)	P value

Total	–	294 (72.9)	28/204(13.7)	60/205(29.3)	< 0.001


Factor	Coefficient

Range (native)	1.122

Fish (present)	0.106

Food Quality (low)	1.128

Range*Fish	0.042

Range*Food Quality	−1.178

Fish*Food Quality	−0.988

Range*Fish*Food Quality	1.254


EGFR/ACTB (cutoff 0.05)	EFEMP1/ACTB (cutoff 0.06)

All gliomasa	All gliomas	GBM(95 pts, 88 died)	AA(36 pts, 23 died)	OT(35 pts, 18 died)


Carbon source	Dry weight of mycelial mat (mg/flask)	Protein content (mg/ml)	Cellulase

aFPase (FPU/ml)	bCMCase (U/ml)	cΒ-glucosidase (U/ml)


Source	WT categories	Sample size	HR (95%CI)

OS	DFS/RFS/EFS

Pronzato et al. [13] 1989	≤35 days	116	Reference	−


Study groups	No. tested/no. (%) seropositive


Thyroid lesions simulating a squamoid pattern	Differential features

Pure squamous cells carcinoma	(i) Entirely composed of squamous cells; (ii) no evidence of another type of thyroid carcinoma in close proximity.

Primary head and neck squamous cell carcinoma	(i) Presence of in situ component in head and neck structures;(ii) features of “ab extrinseco” involvement of thyroid parenchyma; (iii) PAX8 is consistently negative.

Metastatic squamous cell carcinoma of the lung	(i) Presence of a lung nodule clinically detected;(ii) PAX8 is consistently negative.

Diffuse sclerosing variant of papillary thyroid carcinoma	(i) Abundant psammoma bodies;(ii) neoplastic cells retain nuclear features of PTC;(iii) immunoreactivity for thyroglobulin.

Mucoepidermoid carcinoma	(i) Combination of squamoid and mucinous components; (ii) thought to represent papillary carcinoma with extreme degree of squamous and mucinous metaplasia; (iii) low grade thyroid neoplasm.

Sclerosing mucoepidermoid carcinoma with eosinophilia	(i) Fibrohyaline stroma;(ii) striking infiltration of eosinophils; (iii) mucin secretion is often present; (iv) typically arising in Hashimoto thyroiditis (thought to derive from metaplastic squamous nests associated with inflammatory infiltrate).

CASTLE(carcinoma with thymus-like elements)	(i) Lymphoepithelioma-like carcinoma with foci of squamous differentiation; (ii) pushing margins; (iii) immunoreactivity for CD5, bcl-2, high molecular weight keratin, mcl-1 (thought to be ectopic thymic carcinoma arising from remnants of the branchial pouch); (iv) usually indolent behavior with tendency to late recurrences.

Thyroid lesions simulating a squamoid pattern	Differential features

Sclerosing mucoepidermoid carcinoma with eosinophilia	(i) Fibrohyaline stroma;(ii) striking infiltration of eosinophils; (iii) mucin secretion is often present; (iv) typically arising in Hashimoto thyroiditis (thought to derive from metaplastic squamous nests associated with inflammatory infiltrate).

CASTLE(carcinoma with thymus-like elements)	(i) Lymphoepithelioma-like carcinoma with foci of squamous differentiation; (ii) pushing margins; (iii) immunoreactivity for CD5, bcl-2, high molecular weight keratin, mcl-1 (thought to be ectopic thymic carcinoma arising from remnants of the branchial pouch); (iv) usually indolent behavior with tendency to late recurrences.


Terms of Delivery	Trichomonas vaginalis infection	P-value

Study group (positive cases)	Control group (negative cases)

No.	(%)	No.	(%)

Preterm birth	19	(54.28)	36	(13.58)	0.001

Full term birth	14	(40)	216	(81.5)	0.001

Post term birth	2	(5.7)	13	(4.9)	0.83

Total	35	(100)	265	(100)

Terms of Delivery	Trichomonas vaginalis infection	P-value

Study group (positive cases)	Control group (negative cases)

No.	(%)	No.	(%)

Preterm bi			3	(13.58)	0.00


Assumptions	Projected reduction in diabetes prevalence compared to no intervention

Moderate-risk [millions]	High-risk [millions]	Population [millions]	Combined [millions]

Base case assumptions:

Flat background diabetes incidence rate*	1.2 [3.1]	0.5 [1.2]	0.3 [0.7]	1.4 [3.6]

Lifestyle intervention will reduce yearly diabetes incidence rate by 12.5% in target population

Population-wide intervention will reduce the yearly diabetes incidence rate by 2% among all US adults

Adjustments to base case assumptions

Increasing background incidence rate*	1.4 [3.7]	0.5 [1.4]	0.3 [0.8]	1.6 [4.2]

Lifestyle intervention will reduce yearly diabetes incidence rate by 25% in target population	2.5 [6.4]	1.0 [2.6]	0.3 [0.7]	2.7 [6.9]

Lifestyle intervention will reduce yearly diabetes incidence rate by 6.25% in target population	0.6 [1.5]	0.3 [0.6]	0.3 [0.7]	0.8 [2.0]

Population-wide intervention will reduce yearly diabetes incidence rate by 1% among all US adults	1.2 [3.1]	0.5 [1.2]	0.2 [0.3]	1.1 [2.8]

Population-wide intervention will reduce yearly diabetes incidence rate by 4% among all US adults	1.2 [3.1]	0.5 [1.2]	0.6 [1.4]	1.6 [4.0]

Assumptions	Projected reduction in diabetes prevalence compared to no intervention

Moderate-risk [millions]	High-risk [millions]

Base case assumptions:

Flat background diabetes incidence rate*	1.2 [3.1]	0.5 [1.2]

Lifestyle intervention will reduce yearly diabetes incidence rate by 12.5% in target population

Population-wide intervention will reduce the yearly diabetes incidence rate by 2% among all US adults

Adjustments to base case assumptions

Increasing background incidence rate*	1.4 [3.7]	0.5 [1.4]

Lifestyle intervention will reduce yearly diabetes incidence rate by 25% in target population	2.5 [6.4]	1.0 [2.6]

Lifestyle intervention will reduce yearly diabetes incidence rate by 6.25% in target population	0.6 [1.5]	0.3 [0.6]

Population-wide intervention will reduce yearly diabetes incidence rate by 1% among all US adults	1.2 [3.1]	0.5 [1.2]

Population-wide intervention will reduce yearly diabetes incidence rate by 4% among all US adults	1.2 [3.1]	0.5 [1.2]

Projected reduction in diabetes prevalence compared to no intervention

Population [millions]	Combined [millions]

Base case assumptions:

0.3 [0.7]	1.4 [3.6]

Adjustments to base case assumptions

0.3 [0.8]	1.6 [4.2]

0.3 [0.7]	2.7 [6.9]

0.3 [0.7]	0.8 [2.0]

0.2 [0.3]	1.1 [2.8]

0.6 [1.4]	1.6 [4.0]


	Target head angle (degrees)

	−80	−60	−40	−20	0	20	40

Pitch experiment

Qualitative descriptions	11	12	12	11	12	11	12

Switch‐press measures

DI, MV, PV, D	8	8	12	10	12	11	11

OF, in‐phase	7	3	10	9	10	2	4

OF, out‐phase	5	3	7	7	8	3	2

Roll experiment

Qualitative descriptions	N/A	N/A	10	11	11	11	10

Switch‐press measures

DI, MV, PV, D	N/A	N/A	10	11	11	11	10

OF, in‐phase	N/A	N/A	8	8	10	8	4

OF, out‐phase	N/A	N/A	5	7	8	8	6

	Target head angle (degrees)

	−80	−60	−40	−20	0	20	40

Pitch experiment

Qualitative descriptions	11	12	12	11	12	11	12

Switch‐press measures

DI, MV, PV, D	8	8	12	10	12	11	11

OF, in‐phase	7	3	10	9	10	2	4

OF, out‐phase	5	3	7	7	8	3	2

Roll experiment

Qualitative descriptions	N/A	N/A	10	11	11	11	10

Switch‐press measures

DI, MV, PV, D	N/A	N/A	10	11	11	11	10

OF, in	N		8	8

	Target head angle (degrees)

	−80	−60	−40	−20	0	20	40

‐phase	/A	N/A			10	8	4

OF, out‐phase	N/A	N/A	5	7	8	8	6


	Ofloxacin	Injectable drugs	TotalResistance to either Fluoroquinolone or injectable drugsN (%)

	OfloxacinR, n (%)	KanamycinR, n (%)	CapreomycinR, n (%)

New MDR patients (n = 5)	0 (0)	0 (0)	0	0 (0)

Previously treated MDR patients (n = 33)	1 (3)	1 (3)	5 (15.2)	7 (21.2)

Total	1	1	5	7 (18.4)

	Ofloxacin	Injectable drugs	TotalResistance to either Fluoroquinolone or injectable drugsN (%)

	OfloxacinR, n (%)	KanamycinR, n (%)	CapreomycinR, n (%)

New MDR patients (n = 5	0	0 (	0	0 (0)

	Ofloxacin	Injectable drugs	TotalResistance to either Fluoroquinolone or injectable drugsN (%)

	OfloxacinR, n (%)	KanamycinR, n (%)	CapreomycinR, n (%)

)	 (0)	0)

Previously treated MDR patients (n = 33)	1 (3)	1 (3)	5 (15.2)	7 (21.2)

Total	1	1	5	7 (18.4)


Ectoparasite	 Postlactating females	 Nonreproductive females

	(n = 17)	(n = 97)

Spinturnix americanus	41.2%, 0.5 (0.7, 0–2)	38%, 0.7 (1.2, 0–5)

Myodopsylla insignis	47.1%, 1.1 (1.6, 0–5)	32%, 0.7 (1.3, 0–7)

Macronyssus crosbyi	0	7.2%, 0.1 (0.3, 0–2)

Cimex adjunctus	0	0

Androlaeps casalis	0	1%, 0.02 (0.2, 0–2)

Acanthophthirius spp.	0	1%, 0.02 (0.2, 0–2)

Any ectoparasite	76.5%, 1.6 (1.4, 0–5)	66%, 1.5 (1.7, 0–5)

Ectoparasite	Postlactating females

	(n = 17)

Spinturnix americanus	41.2%, 0.5 (0.7, 0–2)

Myodopsylla insignis	47.1%, 1.1 (1.6, 0–5)

Macronyssus crosbyi	0

Cimex adjunctus	0

Androlaeps casalis	0

Acanthophthirius spp.	0

Any ectoparasite	76.5%, 1.6 (1.4, 0–5)


Finding	Illustrating data

Localized changes, with minimal impact on wider clinical systems or resource-allocation decisions, may be sustained relatively easily	Case D: ‘The long term viability is very, very strong, it's viewed as an essential service, the patients need to be seen by a [clinical specialist in the mainstream clinical area] and they need to be seen by a geneticist, so they either come to our clinic or they get pushed back into the existing clinics. [...] I think we're probably pretty cost neutral for the trust, the activity we're doing is probably no different to what would be happening in the clinic and we're probably a little bit more economically efficient I would guess’. (Mainstream consultant clinical specialist)

Where impact on wider clinical systems and resource-allocation decisions is present, embedding the organizational innovation into the wider clinical system may secure its sustainability	Case C: ‘We've got an established service that everyone knows about, and the route for all these patients is through [Case C service], so there isn't any gynaecologist messing around—in my view, that's what I would have called it, they'd be messing around with patients who had been referred by their GP. Now these patients are all passed through [the service] before they come to gynaecology. So they may still come [to me], but they come with expert information upfront about the risk and the options that they've got available’. (Gynaecological oncologist in referring department)

‘In the end [our case to the commissioners] was more, ‘If you don't fund this there's going to be a great black hole that no-one can pick up’. I think that's how it was funded in the end’. (Lead nurse)

Services that are not embedded into the wider system may be seen as supplementary rather than as a core part of provision, and are more vulnerable to decommissioning	Case B: ‘The money wasn't there, there wasn't identified any money, but I think there's also that it wasn't priority for the Primary Care Trust, nobody had any targets to reach for genetics, there was no ‘must dos’ about genetics and so it was easy for it to slip down the radar. [...] The priorities were the national priorities to do with waiting times, with, cancer, for heart disease, for prevention, so there were quite a large number of priorities for any Primary Care Trust, we didn't have unusual priorities other than the national priorities in health. And there were so many, there still are, but there were so many it's quite hard to do anything other than to meet the priorities’. (PCT former senior clinical manager)

Finding

Localized changes, with minimal impact on wider clinical systems or resource-allocation decisions, may be sustained relatively easily

Where impact on wider clinical systems and resource-allocation decisions is present, embedding the organizational innovation into the wider clinical system may secure its sustainability

Services that are not embedded into the wider system may be seen as supplementary rather than as a core part of provision, and are more vulnerable to decommissioning

Illustrating data

Case D: ‘The long term viability is very, very strong, it's viewed as an essential service, the patients need to be seen by a [clinical specialist in the mainstream clinical area] and they need to be seen by a geneticist, so they either come to our clinic or they get pushed back into the existing clinics. [...] I think we're probably pretty cost neutral for the trust, the activity we're doing is probably no different to what would be happening in the clinic and we're probably a little bit more economically efficient I would guess’. (Mainstream consultant clinical specialist)

Case C: ‘We've got an established service that everyone knows about, and the route for all these patients is through [Case C service], so there isn't any gynaecologist messing around—in my view, that's what I would have called it, they'd be messing around with patients who had been referred by their GP. Now these patients are all passed through [the service] before they come to gynaecology. So they may still come [to me], but they come with expert information upfront about the risk and the options that they've got available’. (Gynaecological oncologist in referring department)

‘In the end [our case to the commissioners] was more, ‘If you don't fund this there's going to be a great black hole that no-one can pick up’. I think that's how it was funded in the end’. (Lead nurse)

Case B: ‘The money wasn't there, there wasn't identified any money, but I think there's also that it wasn't priority for the Primary Care Trust, nobody had any targets to reach for genetics, there was no ‘must dos’ about genetics and so it was easy for it to slip down the radar. [...] The priorities were the national priorities to do with waiting times, with, cancer, for heart disease, for prevention, so there were quite a large number of priorities for any Primary Care Trust, we didn't have unusual priorities other than the national priorities in health. And there were so many, there still are, but there were so many it's quite hard to do anything other than to meet the priorities’. (PCT former senior clinical manager)


No.	Themes	OSPE	OSCE	Frequency	Total

1.	Curriculum

 	 Syllabus	+	++	3	7

 	 Repetition	+++	+	4

2.	Skills assessment

 	 Practical/clinical skills	++	+++	5	12

 	 Concepts	+++	+	4

 	 Competence	++	+	3

3.	Confidence

 	 Confidence	++	+	3	6

 	 Comfort	++	+	3

4.	Fairness of exam	++	++	4	4

5.	Impact on learning

 	 Improved learning	+	+	2	5

 	 Future learning	+	++	3

6.	Stress

 	 Stress	++++	++++	8	17

 	 Time	++++++	+++	9

7.	Organisation of exam	++	++	4	4

8.	Examiners’ calibration	+++	++++++++	8	11

No.	Themes	OSPE	OSCE	Frequency

1.	Curriculum

	Syllabus	+	++	3

	Repetition	+++	+	4

2.	Skills assessment

	Practical/clinical skills	++	+++	5

	Concepts	+++	+	4

	Competence	++	+	3

3.	Confidence

	Confidence	++	+	3

	Comfort	++	+	3

4.	Fairness of exam	++	++	4

5.	Impact on learning

	Improved learning	+	+	2

	Future learning	+	++	3

6.	Stress

	Stress	++++	++++	8

	Time	++++++	+++	9

7.	Organisation of exam	++	++	4

8.	Examiners’ calibration	+++	++++++++	8


	Intention to treat	Modified intention to treat

	Antibiotic treatmentn = 22	No antibiotic treatmentn = 36	P value	Antibiotic treatmentn = 18	No antibiotic treatmentn = 26	P value

Tracheostomy	5 (22)	5 (13)	>0.999	5 (27)	5 (19)	0.716

Corticosteroid use	8 (36)	19 (52)	0.283	6 (33)	13 (50)	0.359

Septic shock	1 (4)	7 (19)	0.134	1 (5)	5 (19)	0.375

ICU-acquired infections other than VAT and VAPa	7 (31)	18 (50)	0.274	6 (33)	13 (50)	0.359

 Bacteremia	6 (27)	13 (36)	0.572	5 (27)	8 (30)	>0.999

 Urinary tract infection	2 (9)	5 (13)	0.698	2 (11)	5 (19)	0.682

 Others	2 (9)	2 (5)	>0.999	2 (11)	2 (7)	>0.999

Total duration of antibiotic treatment, days	25 ± 14	19 ± 15	0.149	24 ± 15	17 ± 15	0.104

Antibiotic treatment before VAT	18 (81)	29 (80)	>0.999	15 (83)	23 (88)	0.676

Antibiotic treatment during the 8 days following random assignment	22 (100)	21 (58)	<0.001	18 (100)	10 (38)	<0.001

Reasons for antibiotic treatment during the 8 days following random assignment

 VAT	22 (100)	0 (0)	<0.001	18 (100)	0 (0)	<0.001

 VAP	0 (0)	15 (41)	<0.001	0 (0)	10 (38)	0.003

 Other infections	0 (0)	6 (16)	0.073	0 (0)	0 (0)	NA

Antibiotic treatment after day 8 post-random assignment	6 (27)	8 (22)	0.756	3 (16)	5 (19)	>0.999


Site	Ever smoked cigarettes, even one or two puffs	Ever smokers who initiated smoking before age 10	Never smokers susceptible to initiate smoking in the next year

Huancayo, 2000	47.1 (40.9–53.5) (n = 963)	18.1 (13.6–23.6) (n = 429)	29.7 (24.8–35.1) (n = 495)

Lima, 2000	54.6 (49.5–59.6) (n = 1,189)	13.5 (11.1–16.4) (n = 605)	25.4 (20.6–31.0) (n = 545)


	Response rate	NR

	Prosody+	Prosody−	Prosody+	Prosody−

Healthy controls (CI 95%)	96 ± 4 (94, 98)	84 ± 7 (81, 87)	3 ± 4(2, 2)	10 ± 7(7, 14)

Patients with schizophrenia (CI 95%)	78 ± 16 (70, 86)	58 ± 19 (49, 67)	22 ± 17 (14, 30)	37 ± 20 (28, 47)


Clinical trials	Interventions	URL

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study	Radiation: 124I-MIBG (no-carrier added)Radiation: 124I-MIBG (carrier added)	https://ClinicalTrials.gov/show/NCT01583842

European Low and Intermediate Risk Neuroblastoma Protocol (low and intermediate pediatric NB and neonatal suprarenal masses)	Drug: chemotherapy	https://ClinicalTrials.gov/show/NCT01728155

Phase II Study of Proton Radiation Therapy for Neuroblastoma	Radiation: proton beam radiation therapy	https://ClinicalTrials.gov/show/NCT02112617

Immunomonitoring of Children With Neuroblastoma	Immunological analyses	https://ClinicalTrials.gov/show/NCT01295762

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma	Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH	https://ClinicalTrials.gov/show/NCT00911560

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma	Laboratory biomarker analysis; cytology specimen collection procedure	https://ClinicalTrials.gov/show/NCT00904241

Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma	Drug: dasatinibDrug: rapamycinDrug: irinotecanDrug: temozolomideDrug: irinotecanDrug: temozolomide	https://ClinicalTrials.gov/show/NCT01467986

Study of DNA in Blood Samples From Patients With Neuroblastoma	Laboratory biomarker analysisGenetic: polymerase chain reactionGenetic: polyacrylamide gel electrophoresisGenetic: DNA analysis	https://ClinicalTrials.gov/show/NCT00898391

Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine-Positron Emission Tomography (FLT-PET)	Device: FLT-PET	https://ClinicalTrials.gov/show/NCT01308905

Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma	Drug: fenretinide Lym-X-Sorb oral powderDrug: ketoconazole	https://ClinicalTrials.gov/show/NCT02075177

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults with Neuroblastoma and Osteosarcoma	Biological: IL-2Biological: GD2Bi-aATCBiological: GM-CSFOther: laboratory evaluations of immune responses	https://ClinicalTrials.gov/show/NCT02100930

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma	Biological: anti-GD2 3F8 monoclonal antibodyDrug: GM-CSF (granulocyte-macrophage colony-stimulating factor)Drug: oral isotretinoin	https://ClinicalTrials.gov/show/NCT02100930

Fenretinide Lym-X-Sorb+Ketoconazole+Vincristine for Recurrent or Resistant Neuroblastoma	Drug: fenretinide/LXS oral powderDrug: ketoconazoleDrug: vincristine	https://ClinicalTrials.gov/show/NCT02163356

Pilot Study of Activated T-Cell Therapy for Refractory/Relapsed Neuroblastoma	Biological: activated T lymphocyte	https://ClinicalTrials.gov/show/NCT01802138

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN	Genetic: iC9-GD2 T-cell lymphocytes – frozen cellsGenetic: iC9-GD2 T-cell lymphocytes – fresh cellsDrug: cyclophosphamideDrug: fludarabineDrug: pembrolizumab	https://ClinicalTrials.gov/show/NCT01822652

Clinical trials	Interventions	URL

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patie		https://ClinicalTrials.gov/show/NCT01583842

nts With Neuroblastoma: A Pilot Study	Radiation: 124I-MIBG (no-carrier added)Radiation: 124I-MIBG (carrier added)

European Low and Intermediate Risk Neuroblastoma Protocol (low and intermediate pediatric NB and neonatal suprarenal masses)	Drug: chemotherapy	https://ClinicalTrials.gov/show/NCT01728155

Phase II Study of Proton Radiation Therapy for Neuroblastoma	Radiation: proton beam radiation therapy	https://ClinicalTrials.gov/show/NCT02112617

Immunomonitoring of Children With Neuroblastoma	Immunological analyses	https://ClinicalTrials.gov/show/NCT01295762

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma	Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH	https://ClinicalTrials.gov/show/NCT00911560

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma	Laboratory biomarker analysis; cytology specimen collection procedure	https://ClinicalTrials.gov/show/NCT00904241

Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma	Drug: dasatinibDrug: rapamycinDrug: irinotecanDrug: temozolomideDrug: irinotecanDrug: temozolomide	https://ClinicalTrials.gov/show/NCT01467986

Study of DNA in Blood Samples From Patients With Neuroblastoma	Laboratory biomarker analysisGenetic: polymerase chain reactionGenetic: polyacrylamide gel electrophoresisGenetic: DNA analysis	https://ClinicalTrials.gov/show/NCT00898391

Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine-Positron Emission Tomography (FLT-PET)	Device: FLT-PET	https://ClinicalTrials.gov/show/NCT01308905

Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma	Drug: fenretinide Lym-X-Sorb oral powderDrug: ketoconazole	https://ClinicalTrials.gov/show/NCT02075177

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults with Neuroblastoma and Osteosarcoma	Biological: IL-2Biological: GD2Bi-aATCBiological: GM-CSFOther: laboratory evaluations of immune responses	https://ClinicalTrials.gov/show/NCT02100930

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma	Biological: anti-GD2 3F8 monoclonal antibodyDrug: GM-CSF (granulocyte-macrophage colony-stimulating factor)Drug: oral isotretinoin	https://ClinicalTrials.gov/show/NCT02100930

Fenretinide Lym-X-Sorb+Ketoconazole+Vincristine for Recurrent or Resistant Neuroblastoma	Drug: fenretinide/LXS oral powderDrug: ketoconazoleDrug: vincristine	https://ClinicalTrials.gov/show/NCT02163356

Pilot Study of Activated T-Cell Therapy for Refractory/Relapsed Neuroblastoma	Biological: activated T lymphocyte	https://ClinicalTrials.gov/show/NCT01802138

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN	Genetic: iC9-GD2 T-cell lymphocytes – frozen cellsGenetic: iC9-GD2 T-cell lymphocytes – fresh cellsDrug: cyclophosphamideDrug: fludarabineDrug: pembrolizumab	https://ClinicalTrials.gov/show/NCT01822652


Capacity areas/skills for HPSR+A	Proportion of staff requiring additional training (n = 123), n (%)

HPSR+A technical skills and conceptual underpinnings,

 e.g. what is HPSR+A and what constitutes HPSR+A approaches to research and teaching	101 (82.0)

HPSR+A research and writing

 Writing research methodologies	84 (68.0)

 Writing briefing notes for politicians, policymakers, external funders and donors

80 (65.0)

 Writing papers for academic journals	78 (63.0)

Management and administration

 Leadership	92 (75.0)

 Effective networking	94 (76.0)

Financial and information management

 Identifying and applying for external funding sources	95 (77.0)

 Creating and managing effective and efficient financial reporting systems	91 (74.0)

 Creating and managing effective internal information systems	101 (82.0)

Capacity areas/skills for HPSR+A

HPSR+A technical skills and conceptual underpinnings,

e.g. what is HPSR+A and what constitutes HPSR+A approaches to research and teaching

HPSR+A research and writing

Writing research methodologies

Writing briefing notes for politicians, policymakers, external funders and donors

Writing papers for academic journals

Management and administration

Leadership

Effective networking

Financial and information management

Identifying and applying for external funding sources

Creating and managing effective and efficient financial reporting systems

Creating and managing effective internal information systems


Marital status

Single	14	4.3	1.12

Married	264	8.2	1.51

Other	16	4.8	1.18

Unknown	12	3.6	1.03

Ethnicity

Afro-Trinidadian	80	24.3	2.36

Indo-Trinidadian	238	72.3	2.47

Other (including mixed race)	11	3.3	0.98

Highest level of education

Primary	213	64.7	2.63

Secondary	103	31.2	2.56

Other	2	0.6	0.43

Unknown	6	1.8	0.73

Employment status

Employed	62	18.8	2.15

Unemployed	256	77.8	2.29

Unknown	11	3.3	0.98

Religion

Hindu	180	54.7	2.74

Islam	27	8.2	1.51

Christian	75	22.8	2.31

Other	39	11.9	1.79

Unknown	8	2.4	0.84


Treatment	Dose mg kg−1	Cotton pellet granuloma

Weight of pellets Mean ± SEM

Control	0.3 mL	51.73 ± 2.35

Indomethacin	10	19.82 ± 2.52 (61.68)b

EEDR	100	37.24 ± 2.00 (27.99)NS

EEDR	200	30.85 ± 3.72 (40.36)b

EEDR	400	29.77 ± 3.76 (42.44)a

Treatment	Dose mg kg−1	Cotton pellet granuloma

Weight of pellets Mean ± SEM

Control	0.3 mL	51.73 ± 2.35

Indomethacin	10	19.82 ± 2.52 (61.68)b

EEDR	100	37.24 ± 2.00 (27.99)NS

EEDR	2	30.85 ± 3.72 (40.36

Treatment	Dose mg kg−1	Cotton pellet granuloma

Weight of pellets Mean ± SEM

	00	)b

EEDR	400	29.77 ± 3.76 (42.44)a


Successful Aging Approach	Definition	References

Biomedical	Absence of multi-morbidity	[6]

Psycho-Cognitive	Absence of depression, absence of anxiety, no cognitive impairment, regular functioning, quality of life, resilience	[3,12,14,38]

Lay View Approach	Presence of well-being, good self perceived health	[8,12]

Combined Approach	Optimal functioning	[6,12]

Successful Aging Approach	Definition	References

Lay View Approach	Presence of well-being, good self perceived health	[8,12]

Combined Approach	Optimal functioning	[6,12]


Country and Year	Criteria used for identifying asymptomatic malaria cases	Study subjects, sample size	Follow-up protocol and duration	Ref.

Africa

Gabon, 2003	No clinical symptoms of malaria with a P. falciparum positive blood smear, asymptomatic for at least 5 days during follow-up.	Children6 months to 10 years, N = 60	Examined once daily for 7 days thereafter, once every 2 days	[37]

Tanzania, 2006	Presence of P. falciparum on blood smear, axillary temperature of < 37.5°C, and no other symptoms or signs of malaria	Children4-59 months,N = 127	No follow-up.	[33]

South America

Brazilian Amazon, 2002	Individuals positive by microscopy, and/or positive by PCR; and individuals negative by microscopy that subsequently became positive by PCR.	All age groups,N = 172	Follow-up to day 10 and 60.	[21]

Colombia, 2008	Presence of microscopic asexual parasite stages of P. falciparum, P. vivax or P. malariae or of mixed infections in blood, which persisted for at least two weeks without causing any symptoms, or as the detection of parasite DNA by PCR on day 0 in people who remained asymptomatic during the follow-up period.	Individuals2-78 years,N = 21	Follow-up on days 14 and 28.	[19]

Asia

Papua, 2003	No fever history or treatment for malaria within the past week, no clinical evidence of malaria or other infection, no diarrhea, and no current pregnancy but both P. falciparum and P. vivax positive individuals	Adults> 16 years,N = 105	Supervised overnight at local health center. A third axillary temperature was recorded the following morning.	[38]

Indonesia, 2010	Presence of asexual P. falciparum or P. vivax parasitemia in the absence of fever (temperature ≤ 37.9°C) and of clinical signs or symptoms suggestive for malaria or another infectious disease.	Children5-15 years,N = 381	No follow-up.	[27]

Country	Crite	Study subject	Follow-up protocol and durati	Ref

 and Year	ria used for identifying asymptomatic malaria cases	s, sample size	on	.

Africa

Gabon, 2003	No clinical symptoms of malaria with a P. falciparum positive blood smear, asymptomatic for at least 5 days during follow-up.	Children6 months to 10 years, N = 60	Examined once daily for 7 days thereafter, once every 2 days	[37]

Tanzania, 2006	Presence of P. falciparum on blood smear, axillary temperature of < 37.5°C, and no other symptoms or signs of malaria	Children4-59 months,N = 127	No follow-up.	[33]

South America

Brazilian Amazon, 2002	Individuals positive by microscopy, and/or positive by PCR; and individuals negative by microscopy that subsequently became positive by PCR.	All age groups,N = 172	Follow-up to day 10 and 60.	[21]

Colombia, 2008	Presence of microscopic asexual parasite stages of P. falciparum, P. vivax or P. malariae or of mixed infections in blood, which persisted for at least two weeks without causing any symptoms, or as the detection of parasite DNA by PCR on day 0 in people who remained asymptomatic during the follow-up period.	Individuals2-78 years,N = 21	Follow-up on days 14 and 28.	[19]

Asia

Papua, 2003	No fever history or treatment for malaria within the past week, no clinical evidence of malaria or other infection, no diarrhea, and no current pregnancy but both P. falciparum and P. vivax positive individuals	Adults> 16 years,N = 105	Supervised overnight at local health center. A third axillary temperature was recorded the following morning.	[38]

Indonesia, 2010	Presence of asexual P. falciparum or P. vivax parasitemia in the absence of fever (temperature ≤ 37.9°C) and of clinical signs or symptoms suggestive for malaria or another infectious disease.	Children5-15 years,N = 381	No follow-up.	[27]


Samples	Inhibition zones ± (mm)1

E. coliCCMB261	S. aureus CCMB262	S. aureus CCMB263	P. aeruginosaCCMB268	C. albicansCCMB286	C. parapsilosisCCMB288

L. alnifolia leaves	R	10.2 ± 1.3	10 ± 0.5	R	R	R

L. alnifolia stems	R	12.3 ± 1.0	13.9 ± 0.8	R	R	R

L. alnifolia flowers	R	8.4 ± 0.9	R	R	R	6.9 ± 0.1

L. origanoides leaves	R	13.0 ± 0.5	12.0 ± 0.9	R	11.7 ± 0.4	7.1 ± 0.4

L. origanoides stems	R	R	R	R	R	R

L. thymoides  leaves	R	11.2 ± 1.0	9.7 ± 1.3	R	R	R

L. thymoides stems	R	8.7 ± 0.6	R	R	R	R

L. thymoides  flowers	R	8.5 ± 1.5	R	R	R	R

Cloramphenicol2	15.8 ± 1.7	22.6 ± 2.2	R	8.5 ± 0.9	—	—

Nystatin3	—	—	—	—	17.5 ± 0.9	16.6 ± 0.9

Samples	Inhibition zones ± (mm)1

E. coliCCMB261	S. aureus CCMB262	S. aureus CCMB263	P. aeruginosaCCMB268	C. albicansCCMB286	C. parapsilosisCCMB288

L. thymoides  flowers	R	8.5 ± 1.5	R	R	R	R

Cloramphenicol2	15.8 ± 1.7	22.6 ± 2.2	R	8.5 ± 0.9	—	—

Nystatin3	—	—	—	—	17.5 ± 0.9	16.6 ± 0.9


Characteristics	n (N = 157)	%

Age	<19 years	3	1.9

20–24 years	104	66.3

25–29 years	47	29.9

>30 years	3	1.9

Gender	Male	67	42.7

Female	88	56.1

Marital status	Divorced	2	1.3

Not Married	151	96.2

Married	4	2.5

Educational level	Bachelor degree	120	76.4

Master degree	14	8.9

Doctor degree	23	14.6

Work experience in the health sector	<6 months	52	33.1

6–12 months	53	33.8

12–24 months	44	28.0

24–36 months	3	1.9

>36 months	5	3.2

Hours worked daily	<6 h	9	5.7

6–8 h	86	54.8

8–10 h	41	26.1

10–12 h	18	11

>12 h	3	1.9

Night shifts/week	<1	34	21.7

1	71	45.2

>1	46	29.3

0	6	3.8

Clinic service visits/week	<5	99	63.1

5–9	19	12.1

10–14	7	4.5

15–19	6	3.8

>20	26	16.6

Discharges/month	<5	49	31.2

5–9	35	22.3

10–14	24	15.3

15–19	15	12.1

>20	30	19.1


Neonatal characteristic 	Newborn-monotherapy dyadsMean (SE) or n (%)	Newborn-triple therapy dyadsMean (SE) or n (%)	p value

Gender

 Male	45 (53%)	18 (49%)	NS

Gestational age (weeks)∗	38 (0.2)	37 (0.5)	<0.01

Birth weight (g)∗	3079 (63)	2864 (96)	NS

Small for gestational age	18 (21%)	3 (8%)	NS

Toxicology screen

 Positive	10 (12%)	23 (62%)	<0.05

NICU admission	19 (22%)	20 (54%)	<0.01

Length of stay in hospital (days)∗	3 (0.5)	8 (2)	<0.05

CPS involved	15 (18%)	26 (70%)	<0.01


ARV site	Total number of patients

Thamaga primary hospital	1646

Nkoyaphiri clinic	1726

Gabane clinic	392

Thamaga clinic	114

Mmankgodi clinic	70

Kopong clinic	200

Mmopane clinic	120

Total	4268

ARV site

Thamaga primary hospital

Nkoyaphiri clinic

Gabane clinic

Thamaga clinic

Mmankgodi clinic

Kopong clinic

Mmopane clinic

Total


Group	No. mice	Vaccine and administration	Anti‐HCV Abs	Days post‐prime

Prime	2xboost	0	14	28	42

				Serum IgM	0/5	0/5	0/5	0/5

0	5			Serum IgG	0/5	0/5	0/5	0/5

				Faeces IgA	0/5	0/5	0/5	0/5

		im	Feeding	Serum IgM	0/5	5/5	5/5	5/5

1	5	HEK293T‐E1E2	Lettuce E1E2	Serum IgG	0/5	0/5	0/5	4/5

				Faeces IgA	0/5	4/5	4/5	4/5

		Feeding		Serum IgM	0/7	0/7	1/7	2/7

2	7	Lettuce‐E1E2∆N6		Serum IgG	0/7	0/7	0/7	0/7

				Faeces IgA	0/7	3/7	3/7	3/7

		Feeding		Serum IgM	0/5	0/5	1/5	1/5

3	5	Lettuce‐E1E2		Serum IgG	0/5	0/5	0/5	0/5

				Faeces IgA	0/5	0/5	0/5	0/5

4	5	im	im	Serum IgM	0/5	ND	5/5	5/5

		HEK293T‐E1E2	HEK293T‐E1E2	Serum IgG	0/5	ND	5/5	5/5

				Faeces IgA	ND	ND	5/5	5/5

Group	No. mice	Prime	2xboost	Anti‐HCV Abs	0	14	28	42

				Serum IgM	0/5	0/5	0/5	0/5

0	5			Serum IgG	0/5	0/5	0/5	0/5

				Faeces IgA	0/5	0/5	0/5	0/5

		im	Feeding	Serum IgM	0/5	5/5	5/5	5/5

1	5	HEK293T‐E1E2	Lettuce E1E2	Serum IgG	0/5	0/5	0/5	4/5

				Faeces IgA	0/5	4/5	4/5	4/5

		Feeding		Serum IgM	0/7	0/7	1/7	2/7

2	7	Lettuce‐E1E2∆N6		Serum IgG	0/7	0/7	0/7	0/7

				Faeces IgA	0/7	3/7	3/7	3/7

		Feeding		Serum IgM	0/5	0/5	1/5	1/5

3	5	Lettuce‐E1E2		Serum IgG	0/5	0/5	0/5	0/5

				Faeces IgA	0/5	0/5	0/5	0/5

4	5	im	im	Serum IgM	0/5	ND	5/5	5/5

		HEK293T‐E1E2	HEK293T‐E1E2	Serum IgG	0/5	ND	5/5	5/5

				Faeces IgA	ND	ND	5/5	5/5


species	factors associated with chick-a-dee call variation	references

black-capped chickadee Poecile atricapillus	species	[48,68–70]

flock	[71,72]

individual	[73]

predator	[74–76]

boreal chickadee P. hudsonicus	individual	[77]

chestnut-backed chickadee P. rufescens	individual	[78]

Carolina chickadee P. carolinensis	species	[48]

local population	[79]

individual	[80]

energetic state	[81]

predator	[82–85]

food	[87,88]

flight	[59,82]

Mexican chickadee P. sclateri	individual	[89]

mountain chickadee P. gambeli	species	[68,69]

individual	[90]

flight	[91]

tufted titmouse Baeolophus bicolor	individual	[92]

predator	[83,93,94]

crested tit Lophophanes cristatus	proximity to cover	[95,96]

willow tit Poecile montana	predator	[97]

species	factors associated with chick-a-dee call variation	references

black-capped chickadee Poecile atricapillus	species	[48,68–70]

flock	[71,72]

individual	[73]

predator	[74–76]

boreal chickadee P. hudsonicus	individual	[77]

chestnut-backed chickadee P. rufescens	individual	[78]

Carolina chickadee P. carolinensis	species	[48]

local population	[79]

individual	[80]

energetic state	[81]

predator	[82–85]

food	[87,88]

flight	[59,82]

Mexican chickadee P. sclateri	individual	[89]

mou	species	[68,69]

i	[90

ntain chickadee P. gambeli	ndividual	]

flight	[91]

tufted titmouse Baeolophus bicolor	individual	[92]

predator	[83,93,94]

crested tit Lophophanes cristatus	proximity to cover	[95,96]

willow tit Poecile montana	predator	[97]


 	n	%*

Number of patients	635

Median age at time of VIT-initiation (years) (range)	39	(5–77)

Male/female	322/313

Results of allergy testing

 Vespula (vulgaris/germanica) mono sensitization	251	39.5

 Honey bee (Apis mellifera) mono sensitization	33	5.2

 Double sensitization	351	55.3

Severity of anaphylaxis to pre-VIT index field sting

 Large local reaction	8	1.3

 Grade I (mild)	171	26.9

 Grade II (moderate)	321	50.6

 Grade III (severe)	135	21.3

Treatment course

 Mean duration of VIT (years) (range)	3.9	(3–13)

 Mean observation time after VIT (years) (range)	7.0	(0–17)

Number of patients

Median age at time of VIT-initiation (years) (range)

Male/female

Results of allergy testing

Vespula (vulgaris/germanica) mono sensitization

Honey bee (Apis mellifera) mono sensitization

Double sensitization

Severity of anaphylaxis to pre-VIT index field sting

Large local reaction

Grade I (mild)

Grade II (moderate)

Grade III (severe)

Treatment course

Mean duration of VIT (years) (range)

Mean observation time after VIT (years) (range)


Disease	No. withdrawals/treated patients	Inefficacy or loss of efficacy	Adverse event	Persistent remission	On-demand treatment	Patient request	Switch to canakinumab

AOSD	20/35	14	3	1	0	2	2

Gout	18/28	0	0	17	1	0	0

SJIA	16/26	7	3	5	0	1	6

CAPS	11/21	1	1	1	0	8	3

MKD	7/10	2	2	0	0	3	4

FMF	6/13	1	3	0	1	1	3

SAPHO	7/9	5	2	0	0	0	0

Schnitzler’s syndrome	3/7	1	2	0	0	0	1

Spondylo arthritis	5/5	2	3	0	0	0	0

Vasculitis	2/4	2	0	0	0	0	2

Chondro calcinosis	2/4	1	0	1	0	0	0

TRAPS	1/3	1	0	0	0	0	0

GPP	2/3	1	0	1	0	0	0

Polychondritis	1/3	1	0	0	0	0	0

NAPS12	2/2	2	0	0	0	0	0

Disease	No. withdrawals/treated patients	Inefficacy or loss of efficacy	Adverse event	Persistent remission	On-demand treatment	Patient request	Switch to canakinumab

Schnitzler’s syndrome	3/7	1	2	0	0	0	1

Spondylo arthritis	5/5	2	3	0	0	0	0

Vasculitis	2/4	2	0	0	0	0	2

Chondro calcinosis	2/4	1	0	1	0	0	0

TRAPS	1/3	1	0	0	0	0	0

GPP	2/3	1	0	1	0	0	0

Polychondritis	1/3	1	0	0	0	0	0

NAPS12	2/2	2	0	0	0	0	0


Patients	NMO/NMOSD	MS

Number	20	8

Age	49.4 ± 3.9	43.0 ± 4.8

Male:Female	4:16	4:4

Disease duration	8.1 ± 2.0	9.9 ± 3.7

Relapses in the last 2 years	1.2 ± 0.3	2.3 ± 0.5

EDSS∗ score in disease remission	3.3 ± 0.5	4.1 ± 1.0

Patients	NMO/NMOSD	MS

Age	49.4 ± 3.9	43.0 ± 4.8

Male:Female	4:16	4:4

Disease duration	8.1 ± 2.0	9.9 ± 3.7

Relapses in the last 2 years	1.2 ± 0.3	2.3 ± 0.5

EDSS∗ score in disease remission	3.3 ± 0.5	4.1 ± 1.0


% Change in relative probability of delivery with a 5-min increase in travel timea

Delivery at any facility	−30.0

Public facility delivery	−28.2

Private facility delivery	−32.9

NGO facility delivery	−28.6

% Change in relative probability of delivery with a 5-min increase in travel timea

Delivery at any facility

Public facility delivery

Private facility delivery

NGO facility delivery

% Change in relative probability of delivery with a 5-min increase in travel timea

−30.0

−28.2

−32.9

−28.6


Cell Types	Species/Cell Lines	Melotonin Effects	Receptor Types	Melatonin Concentrations	References

Leydig cell	mouse	Inhibition of steroid production	Inhibition of StAR protein expression 	Mt1 and/or Mt2	10 nM to 1 μM	[21]

	MA-10		Inhibition of progesterone production	Mt1 and/or Mt2	10 nM to 1 μM	[21]

	Rat	Inhibition of steroid production	Inhibition of androgen production 	-	4 pM to 4 μM	[40]

			Inhibition of GnRH-dependent intracellular Ca2+release 	-	0.2 pM	[46]

	Hamster	Inhibition of steroid production	Stimulation of CRH production	Mt1	1 and 10 μM	[12,54]

			Stimulation of tyrosine phosphatases activity	Mt1	1 and 10 μM	[54]

			Inhibition of erk and jnk phosphorylation	Mt1	1 and 10 μM	[54]

			Downregulation of c-fos and c-jun expression	Mt1	1 and 10 μM	[54]

			Inhibition of StAR, Hsd3b and Hsd17b3 expression	Mt1	1 and 10 μM	[12,54]

			Inhibition of cAMP generation 	Mt1	1 μM	[12]

			Inhibition of androgen production	Mt1	100 pM to 1 μM	[12,54]

Sertoli cell	Rat	Regulation of energy metabolism	Inhibition of basal lactate production	Mt1 and Mt2	1 mM	[33]

			Upregulation of the insulin-stimulated lactate generation	Mt1 and Mt2	1 mM	[33]

			Stimulation of GLUT1 protein expression and glucose consumption		1 mM	[33]

			Inhibition of LDH protein expression and activity	Mt1 and Mt2	1 mM	[33]

			Stimulation of acetate production		1 mM	[33]

		Prevention of testicular damage	Regulation of intracellular redox state	Mt1 and Mt2	1 mM	[33]

	Hamster	Prevention of testicular damage	Stimulation of the responsiveness to FSH during testicular development	-	25 μg daily injection (1 to 15 wk)	[24]

	Bovine	Stimulation of cell growth/proliferation	Downregulation of mRNA P21 expression	Mt1 and Mt2	0.3 to 1 nM	[59]

		Regulation of spermatogenesis	Upregulation of Cyclin D1, Cyclin E, Pdgfa, Dhh, Ocludin and Claudin expression	Mt1 and Mt2	0.3 to 1 nM	[59]

	Goat	Stimulation of SSCs proliferation	Stimulation of GDNF production	Mt1 and Mt2	1 nM and 1 μM	[73]

Cell Types	Species/Cell Lines	Melotonin Effects	Receptor Types	Melatonin Concentrations	References

Leydig cell	mouse	Inhibition of steroid production	Inhibition of StAR protein expression	Mt1 and/or Mt2	10 nM to 1 μM	[21]

	MA-10		Inhibition of progesterone production	Mt1 and/or Mt2	10 nM to 1 μM	[21]

	Rat	Inhibition of steroid production	Inhibition of androgen production	-	4 pM to 4 μM	[40]

			Inhibition of GnRH-dependent intracellular Ca2+release	-	0.2 pM	[46]

	Hamster	Inhibition of steroid production	Stimulation of CRH production	Mt1	1 and 10 μM	[12,54]

			Stimulation of tyrosine phosphatases activity	Mt1	1 and 10 μM	[54]

			Inhibition of erk and jnk phosphorylation	Mt1	1 and 10 μM	[54]

			Downregulation of c-fos and c-jun expression	Mt1	1 and 10 μM	[54]

			Inhibition of StAR, Hsd3b and Hsd17b3 expression	Mt1	1 and 10 μM	[12,54]

			Inhibition of cAMP generation	Mt1	1 μM	[12]

			Inhibition of androgen production	Mt1	100 pM to 1 μM	[12,54]

Sertoli cell	Rat	Regulation of energy metabolism	Inhibition of basal lactate production	Mt1 and Mt2	1 mM	[33]

			Upregulation of the i	Mt1 and Mt2

			nsulin-stimulated lactate generation		1 mM	[33]

			Stimulation of GLUT1 protein expression and glucose consumption		1 mM	[33]

			Inhibition of LDH protein expression and activity	Mt1 and Mt2	1 mM	[33]

			Stimulation of acetate production		1 mM	[33]

		Prevention of testicular damage	Regulation of intracellular redox state	Mt1 and Mt2	1 mM	[33]

	Hamster	Prevention of testicular damage	Stimulation of the responsiveness to FSH during testicular development	-	25 μg daily injection (1 to 15 wk)	[24]

	Bovine	Stimulation of cell growth/proliferation	Downregulation of mRNA P21 expression	Mt1 and Mt2	0.3 to 1 nM	[59]

		Regulation of spermatogenesis	Upregulation of Cyclin D1, Cyclin E, Pdgfa, Dhh, Ocludin and Claudin expression	Mt1 and Mt2	0.3 to 1 nM	[59]

	Goat	Stimulation of SSCs proliferation	Stimulation of GDNF production	Mt1 and Mt2	1 nM and 1 μM	[73]


Demographics

Mean age, years (range)	32 (11–55)

Male : female	43 : 8

Transfusion requirements, units (range)	7 (3–12)

Demographics

Transfusion requirements, units (range)	7 (3–12)


Item	Component

1	2

Pain	0.555	−0.162

Shortness of breath	0.497	−0.318

Weakness or lack of energy	0.547	−0.379

Nausea	0.251	−0.779

Vomiting	0.196	−0.694

Poor appetite	0.398	−0.236

Constipation	0.305	−0.001

Mouth problems	0.558	−0.305

Drowsiness	0.433	−0.320

Poor mobility	0.672	−0.050

Itching	0.361	−0.317

Difficulty sleeping	0.506	−0.386

Restless legs	0.150	−0.223

Feeling anxious	0.537	−0.303

Feeling depressed	0.586	−0.218

Changes in skin	0.329	−0.345

Diarrhoea	0.187	−0.486

Muscle cramps	0.229	−0.358

Item	Component

1	2

Poor appetite	0.398	−0.236

Constipation	0.305	−0.001

Mouth problems	0.558	−0.305

Drowsiness	0.433	−0.320

Poor mobility	0.672	−0.050

Itching	0.361	−0.317

Difficulty sleeping	0.506	−0.386

Restless legs	0.150	−0.223

Feeling anxious	0.537	−0.303

Feeling depressed	0.586	−0.218

Changes in skin	0.329	−0.345

Diarrhoea	0.187	−0.486

Muscle cramps	0.229	−0.358


Measurement	Location	Data points	Sampling rate

Parameter	Method	Performed by	Laboratory	Office	d-1 (overall)	s-1

Physiological

 Sitting time	IPAQ-long	questionnaire - interview	x		1 (4)	n.a.d

 Physical activity	IPAQ-long	questionnaire - interview	x		1 (4)	n.a.d

 Mental workload	NASA-TLX	questionnaire	x		1 (4)	n.a.d

 Salivary cortisol	saliva collection	Salivette + cortisol ELISA	xa		8 (32)	n.a.d

 Heart-rate	ECG	ECG recorder	xb		n.a.c	250

 Body movements	acceleration	ECG recorder	xb		n.a.c	250

Cognitive

 Working speed	text editing task	computer software (matlab)	x		5 (20)	>1000

 Reaction time	Stroop-test	computer software (matlab)	x		5 (20)	>1000

 Attention	d2R-test	test sheet	x		5 (20)	n.a.d

Office based

 Body postures	logging tool	computer software (C#)		x	n.a.c	>1000

 Postural changes	logging tool	computer software (C#)		x	n.a.c	>1000


Patient type	RCTs n (%)

Medical/Surgical	106 (43)

Medical only	56 (23)

 Bronchiolitis	16 (6)

 Sepsis/Shock	13 (5)

 Asthma	8 (3)

 Other medical	19 (8)

Surgical only	60 (24)

Cardiac surgery	46 (19)

Noncardiac surgery	14 (6)

Trauma/Burns only	26 (10)

 Traumatic brain Injury	13 (5)

 Burns	13 (5)


	Neoadjuvant (n = 80)	Adjuvant (n = 90)	P

PHS (days)	11 (7–33)	11 (5–51)	0.920a

PHS with complications (days)	15	17	0.503b

PHS without complications (days)	11	11	0.972a

Patients with complications	15 (18.8%)	20 (22.2%)	0.704

Non-surgical complications

Pneumonia	1 (1.3%)	3 (3.3%)	0.623

Pleural effusion	0 (0.0%)	2 (2.2%)	0.499

Gastrointestinal motility disorders	3 (3.8%)	3 (3.3%)	1.000

Thrombosis	1 (1.3%)	1 (1.1%)	1.000

Renal dysfunction	1 (1.3%)	1 (1.1%)	1.000

Catheter-related sepsis	1 (1.3%)	0 (0.0%)	0.471

Other (urinary, thrombocytopenia)	1 (1.3%)	4 (4.4%)	0.372

Surgical complications

Anastomotic leakage	0 (0.0%)	2 (2.2%)	0.499

Surgical site infection	5 (6.2%)	6 (6.7%)	1.000

Postoperative hemorrhage	3 (3.8%)	1 (1.1%)	0.343

Wound dehiscence	0 (0.0%)	2 (2.2%)	0.499

Lymphorrhea	2 (2.5%)	1 (1.1%)	0.602

Ileus	0 (0.0%)	1 (1.1%)	1.000

Biliary fistula	1 (1.3%)	0 (0.0%)	0.471


 	Pre-supplementation	Post-supplementation

Measure	Subjects reporting GIT symptoms post-supplement (mean)	Subjects GIT symptom free post-supplement (mean)	P value	Subjects reporting GIT symptoms post- supplement (mean)	Subjects GIT symptom free post-supplement (mean)	P value

General health indices

 Neurological index	1.3	0.5	< 0.004	1.0	0.4	ns

Chalder fatigue scale

 Total fatigue scores	14.2	11.8	ns	12.6	8.9	ns

Amino acids

 (Relative % abundance)

 Asparagine	6.60%	4.78%	< 0.03	6.11%	4.89%	ns

 Hydroxylysine	1.62%	1.15%	< 0.05	1.72%	1.32%	ns

 Hydroxyproline	0.58%	0.34%	< 0.04	0.65%	0.52%	ns


Municipality	% Speaking indigenous language	% Speaking Zapotec monolingual	% Speaking Zapotec monolingual	% Of 15 year-old or older who read and write in Spanish	Average number of years in school	% Of the population engaged in primary production activities

 	Year 2000	Year 2000	Year 1950	Year 2000	Year 2000	Year 2000

Juchitán de Zaragoza	70.01	8.81	27.26	52.11	6.26	13.89

San Blas Atempa	92.76	24.87	72.08	39.95	3.56	33.79

Santa María Xadani	97.71	34.07	83.33	32.05	3.36	35.01

Municipality	% Speaking indigenous language	% Speaking Zapotec monolingual	% Speaking Zapotec monolingual	% Of 15 year-old or older who read and write in Spanish	Average number of years in school	% Of the population engaged in primary production activities

	Year 2000	Year 2000	Year 1950	Year 2000	Year 2000	Year 2000

Juchitán de Za	7	8.	2	52.

Municipality	% Speaking indigenous language	% Speaking Zapotec monolingual	% Speaking Zapotec monolingual	% Of 15 year-old or older who read and write in Spanish	Average number of years in school	% Of the population engaged in primary production activities

	Year 2000	Year 2000	Year 1950	Year 2000	Year 2000	Year 2000

ragoza	0.01	81	7.26	11	6.26	13.89

San Blas Atempa	92.76	24.87	72.08	39.95	3.56	33.79

Santa María Xadani	97.71	34.07	83.33	32.05	3.36	35.01


	Total cohort

Demographics

N (%)	2280

Age, mean (SD) [1]	61.1 (17.0)

Gender (male), n (%) [1]	1315 (57.7)

Included at University Medical Centre, n (%)	1860 (81.6)

Co-morbidities, n (%)

COPD [2]	349 (15.3)

Heart failure [1]	329 (14.4)

Liver disease [1]	113 (5.0)

Renal disease [1]	416 (18.2)

Nursing home [2]	138 (6.1)

Immune-compromised [2]	951 (41.7)

Malignancy – [1]	253 (11.1)

Malignancy + [3]	345 (15.1)

DNR status (%) (6)	478 (21.0)

Suspected source of infection, n (%)

Pulmonary	1059 (46.4)

Urogenital	675 (29.6)

Abdominal	396 (17.4)

Skin	198 (8.7)

Neurological	48 (2.1)

other	396 (17.4)

Vital signs on admission

Systolic blood pressure, mean (SD) (241)	131.9 (25.9)

Heart rate, mean (SD) (45)	108.0 (20.3)

Respiratory rate, mean (SD) (558)	24.0 (7.2)

Oxygen saturation, mean (SD) (71)	95.2 (4.8)

Temperature (°C), mean (SD) (94)	38.72 (1.11)

Altered mental status n (%) (420)	370 (16.2)

Laboratory analysis on admission

Lactate (mmol/l), median (IQR) (293)	1.9 (1.4–2.6)

Platelets (×109/l), median (IQR) (41)	209 (151–280)

INR median (IQR), (702)	1.1 (1–1.4)

Creatinine (μg/l), median (IQR) [16]	87 (67–120)

Urea (mmol/l), median (IQR) (40)	7.0 (5.1–10.2)

Band cells >5%, n (%)	179 (7.9)

Bilirubin (μmol/l), median (IQR) (349)	12 (8–19)

Treatment variables

Time to antibiotics (min), median (IQR) [23]	103 (58–167)

Fluid resuscitation (L during ED stay), median (IQR)	1 (0.5–1.5)

Supplementary oxygen (L/min), median (IQR) (85)	3 (0–5)


 	Before	After

N	39249	39249

Analgesics (N, %)

 Represcribed pregabalin use	—	4009 (10.2)

 1-2-line drugs	5416 (13.8)	3213 (8.2)

Continued use	—	1761 (4.5)

New use	—	1348 (3.4)

Changed/added drugs	—	104 (0.3)

 TCAs	837 (2.1)	448 (1.1)

 Gabapentin	355 (0.9)	197 (0.5)

 Neurotropin	3775 (9.6)	2106 (5.4)

 Duloxetine	501 (1.3)	455 (1.2)

 Mexiletine	310 (0.8)	221 (0.6)

 Opioids	8171 (20.8)	5954 (15.2)

Continued use	—	1580 (4.0)

New use	—	2894 (7.4)

Changed/additions of drugs/route	—	1480 (3.8)

 Oral opioids	5008 (12.8)	3350 (8.5)

Continued use	—	1358 (3.5)

New use	—	1649 (4.2)

Changed/added drugs	—	160 (0.4)

Changed/additions of route	—	183 (0.5)

 Nonoral opioids	4737 (12.1)	3368 (8.6)

Continued use	—	702 (1.8)

New use	—	1465 (3.7)

Changed/added drugs	—	527 (1.3)

Changed/additions of route	—	674 (1.7)

 Weak opioids	3238 (8.2)	2377 (6.1)

Continued use	—	710 (1.8)

New use	—	1444 (3.7)

Changed/added drugs	—	76 (0.2)

Changed/additions of the strength	—	147 (0.4)

 Strong opioids	5928 (15.1)	3963 (10.1)

Continued use	—	1010 (2.6)

New use	—	1644 (4.2)

Changed/added drugs	—	1062 (2.7)

Changed/additions of the strength	—	247 (0.6)

	Before	After

N	39249	39249

Analgesics (N, %)

Represcribed pregabalin use	—	4009 (10.2)

1-2-line drugs	5416 (13.8)	3213 (8.2)

Continued use	—	1761 (4.5)

New use	—	1348 (3.4)

Changed/added drugs	—	104 (0.3)

TCAs	837 (2.1)	448 (1.1)

Gabapentin	355 (0.9)	197 (0.5)

Neurotropin	3775 (9.6)	2106 (5.4)

Duloxetine	501 (1.3)	455 (1.2)

Mexiletine	310 (0.8)	221 (0.6)

Opioids	8171 (20.8)	5954 (15.2)

Continued use	—	1580 (4.0)

New use	—	2894 (7.4)

Changed/additions of drugs/route	—	1480 (3.8)

Oral opioids	5008 (12.8)	3350 (8.5)

Continued use	—	1358 (3.5)

New use	—	1649 (4.2)

Changed/added drugs	—	160 (0.4)

Changed/additions of route	—	183 (0.5)

No	4737 (1	3368

noral opioids	2.1)	(8.6)

Continued use	—	702 (1.8)

New use	—	1465 (3.7)

Changed/added drugs	—	527 (1.3)

Changed/additions of route	—	674 (1.7)

Weak opioids	3238 (8.2)	2377 (6.1)

Continued use	—	710 (1.8)

New use	—	1444 (3.7)

Changed/added drugs	—	76 (0.2)

Changed/additions of the strength	—	147 (0.4)

Strong opioids	5928 (15.1)	3963 (10.1)

Continued use	—	1010 (2.6)

New use	—	1644 (4.2)

Changed/added drugs	—	1062 (2.7)

Changed/additions of the strength	—	247 (0.6)


Characteristic	n = 133

Age (years)a	67.2 ± 9.4

Sex

 Male	77

 Female	56

Diagnosis

 Pancreatic carcinoma	49

 Cholangiocarcinoma	49

 Ampullary carcinoma	13

 Intraductal papillary mucinous neoplasm	6

 Neuroendocrine tumor	5

 Others	11

Total bilirubin (mg/dL)a	4.9 ± 5.5

Preoperative biliary drainage

 Yes	93

 No	40

Operation

 PD	20

 SSPPD	41

 PPPD	72

Operation time (min)a	454.3 ± 99.8

Blood loss (mL)a	990.6 ± 701.3

Transfusion

 Yes	33

 No	100

Characteristic	n = 133

Yes	93

No	40

Operation

PD	20

SSPPD	41

PPPD	72

Operation time (min)a	454.3 ± 99.8

Blood loss (mL)a	990.6 ± 701.3

Transfusion

Yes	33

No	100


	Baseline

GFP (n = 4)	Cre (n = 6)

Heart rate (BPM)

Pre	527 ± 13	504 ± 26

Post	495 ± 28	579 ± 10*

Systolic blood pressure (mmHg)

Pre	129 ± 6	128 ± 5

Post	135 ± 5	152 ± 7*

Diastolic blood pressure (mmHg)

Pre	62 ± 7	68 ± 6

Post	68 ± 6	81 ± 8*

Respiratory rate (min−1)

Pre	185 ± 5	199 ± 7

Post	191 ± 3	199 ± 8

Minute volume (au g−1 min−1)

Pre	1.0 ± 0.1	1.0 ± 0.1

Post	1.0 ± 0.1	1.1 ± 0.1


Measure	DF	F	P

DASS-depression	1.61	.24	.79

DASS-anxiety	1.60	1.72	.19

DASS-stress	1.61	2.05	.14

DASS-total	1.60	1.39	.26

FS (Wellbeing)	1.45	.57	.57


Comparison	P-value	Comparison	P-value

Breast/Colon	0.0001	Colon/SCC	0.135

Breast/SCC	0.114	Colon/KA	0.027

Breast/KA	0.0001	KA/SCC	0.0001

Breast (T)/Breast (M)	0.723	MSI-High/MSI-Low	0.443

Comparison	P-value	Comparison	P-value

Breast/Colon	0.0001	Colon/SCC	0.135

Breast/SCC	0.114	Colon/KA	0.027

Brea	0.0	KA/	0.000

st/KA	001	SCC	1

Breast (T)/Breast (M)	0.723	MSI-High/MSI-Low	0.443


	DL-CNN vs RS1	AI-CALS vs RS1	DL-CNN vs RS2	AI-CALS vs RS2

Average minimum distance AVDIST

 Pre-treatment	4.8 ± 1.8mm	5.3 ± 2.7mm	4.9 ± 3.4mm	4.5 ± 1.9mm

 Post-treatment	4.3 ± 1.7mm	4.4 ± 1.8mm	4.7 ± 3.1mm	4.9 ± 3.7mm

 Both	4.6 ± 1.8mm	4.8 ± 2.3mm	4.8 ± 3.2mm	4.7 ± 2.9mm

Jaccard index JACCARD3D

 Pre-treatment	45.3 ± 8.5%	42.5 ± 14.1%	46.8 ± 9.3%	42.8 ± 12.5%

 Post-treatment	29.8 ± 17.7%	32.9 ± 14.8%	28.8 ± 19.7%	28.6 ± 18.2%

 Both	37.5 ± 15.8%	37.7 ± 15.2%	37.8 ± 17.8%	35.7 ± 17.1%

	DL-CNN vs RS1	AI-CALS vs RS1	DL-CNN vs RS2	AI-CALS vs RS2

Average minimum distance AVDIST

Pre-treat	4.8 	5.3 ± 2	4.9 ± 3.	4.5 ± 1.


	Daily Cannabis Users	Cannabis Non-Users

Sample Size (N)	243	244

Gender	81% male; 19% female	51% male; 49% female

Average Age*	M = 37.8, SD = 13.3	M = 28.2, SD = 11.0

Maximum Income Bracket**	M = $44,431, SD = $23,027	M = $39,640, SD = $24,159

Sample Size (N)

Gender

Average Age*

Maximum Income Bracket**


Causative factors	Numbers

Antenatal	38 (11.7 %)

Intrapartum	220 (67.9 %)

 Placental abruption	87

 Cord prolapse	16

 Uterine rupture	15

 Maternal hypoxic event	8

 Fetal exsanguination	8

 Clinical CAM (Group I )	19

 Non clinical CAM (Group II)	67

Perinatal	8 (2.5 %)

 Fetal central nervous system or systemic infection	8

Miscellaneous	58 (17.9 %)

 Suspected CAM	54

 Unknown causes	4

Total	324


Interactions	Patientsn = 624n (%)

Potential drug-drug interactions	492 (78.8)

Number of potential drug-drug interactions*

 1	154 (24.7)

 2	92 (14.7)

 3–4	154 (24.7)

 ≥ 5	92 (14.7)

Type D	24 (3.8)

 ACE* inhibitors + potassium-sparing diuretics (or potassium supplementation)	11 (1.8)

 NSAID*+ Methotrexate	5 (0.8)

 NSAID* +anticoagulants (or glucocorticoids)	5 (0.8)

 β blocking agents + Verapamil (or Fluoxetin)	3 (0.4)

Type C	468 (75.0)

 ACE* inhibitors + NSAID*	252 (40.4)

 NSAID*+ low dose ASA*	212 (34.0)

 NSAID*+ sulfonylureas	128 (20.5)

 ACE* inhibitors + low dose ASA*	130 (20.8)

 β blocking agents + NSAID*	107 (17.1)

 NSAID* + Diuretics	105 (16.8)

 ACE* inhibitors + glybenclamide	68 (10.9)

 NSAID*+ other NSAID*	51 (8.2)

 ACE* inhibitors + thiazide diuretics	47 (7.6)

 Pravastatin + bezafibrate	35 (5.6)

 Pentoxiyilline + antihypertensives	37 (5.9)

 Metformin+ ranitidine	40 (6.5)

 Glibenclamide + antimycotics or cotrimoxazole	24 (3.9)

 Furosemide + ACE* inhibitors	21 (3.4)

 ACE* inhibitors + antiacids	19 (3.1)

 Alendronate + NSAIDs*	18 (2.9)

 Insulin + antihypertensive	18 (2.9)

 Pentoxifylline + hypoglycemic agents	14 (2.2)

 Acetaminophen + carbamazepin	14 (2.2)

 Ranitidine + azole type of antimycotics	11 (1.8)

 Others	61 (9.4)

Potential drug-disease interactions	400 (64.1)

Number of potential drug-disease interactions

 1	346 (55.4)

 ≥ 2	54 (8.7)

NSAIDs* in patients with hypertension and/or chronic heart failure	384 (61.5)

β blocking agents in patients with diabetes mellitus	31 (5.0)

NSAIDs* in patients with chronic renal insufficiency	18 (2.9)

NSAIDs* in patients with previous peptic ulcer	8 (1.3)

Thiazides diuretics in patients with gout	7 (1.1)

Metformin in patients with chronic renal insufficiency or congestive heart failure	6 (1.0)

β blocking agents in patients with peripheral vascular disease	4 (0.6)

β blocking agents in patients with asthma/COPD*	3 (0.5)

Others	5 (1.0)

Interactions

Potential drug-drug interactions

Number of potential drug-drug interactions*

1

2

3–4

≥ 5

Type D

ACE* inhibitors + potassium-sparing diuretics (or potassium supplementation)

NSAID*+ Methotrexate

NSAID* +anticoagulants (or glucocorticoids)

β blocking agents + Verapamil (or Fluoxetin)

Type C

ACE* inhibitors + NSAID*

NSAID*+ low dose ASA*

NSAID*+ sulfonylureas

ACE* inhibitors + low dose ASA*

β blocking agents + NSAID*

NSAID* + Diuretics

ACE* inhibitors + glybenclamide

NSAID*+ other NSAID*

ACE* inhibitors + thiazide diuretics

Pravastatin + bezafibrate

Pentoxiyilline + antihypertensives

Metformin+ ranitidine

Glibenclamide + antimycotics or cotrimoxazole

Furosemide + ACE* inhibitors

ACE* inhibitors + antiacids

Alendronate + NSAIDs*

Insulin + antihypertensive

Pentoxifylline + hypoglycemic agents

Acetaminophen + carbamazepin

Ranitidine + azole type of antimycotics

Others

Potential drug-disease interactions

Number of potential drug-disease interactions

1

≥ 2

NSAIDs* in patients with hypertension and/or chronic heart failure

β blocking agents in patients with diabetes mellitus

NSAIDs* in patients with chronic renal insufficiency

NSAIDs* in patients with previous peptic ulcer

Thiazides diuretics in patients with gout

Metformin in patients with chronic renal insufficiency or congestive heart failure

β blocking agents in patients with peripheral vascular disease

β blocking agents in patients with asthma/COPD*

Others


District	Number	Percent

Gulu

Total anaemia	117	32.9

Mild anaemia	82	23.0

Moderate anaemia	32	9.0

Severe anaemia	3	0.8

Hoima

Total anaemia	47	12.1

Mild anaemia	35	9.0

Moderate anaemia	10	2.5

Severe anaemia	2	0.5

District	Number	Percent

Total anaemia	47	12.1

Mild anaemia	35	9.0

Moderate anaemia	10	2.5

Severe anaemia	2	0.5


Gene type	Number of genes*	Differentially expressed*	Enrichment p-value**	Enrichment status+

Housekeeping	3292	29	1.60E-13	Depleted

Weak promoter	5262	118	0.07	Depleted

Narrow promoter	930	43	1.20E-04	Enriched

Broad promoter	1279	51	9.50E-04	Enriched

Bivalent	3400	166	4.90E-18	Enriched


	CT	MRI	DSA

unenhanced	enhancement	unenhanced	Gd-DTPA-enhanced	enhancement

shape	border	density	Arterial phase	Venous phase	shape	border	T1WI	T2WI	DWI	Arterialphase	Venousphase	Delayphase

case1	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	hyper	moderate	hyper

case2	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case3	M-R	well	hypo	hetero	moderate	Lob	well	hypo	hyper	hyper	hetero	moderate	mild	hyper

case4	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	hyper	moderate	hyper

case5	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	hyper	moderate	hyper

case6	M-O	well	hypo	hetero	moderate	M-N	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case7	M-O	well	hetero, hypo	hetero	moderate	M-N	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case8	S-R	well	hypo	homo	mild	nodule	well	hypo	hyper	hyper	homo	moderate	mild	hyper

case9						M-N	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case10						M-N	well	hypo	hyper	sig. Hyper	hetero	mild	mild	hyper

case11						Irr	well	hetero	hyper	hyper	hetero	hetero	hetero	hetero

	CT	MRI	DSA

unenhanced	enhancement	unenhanced	Gd-DTPA-enhanced	enhancement

shape	border	density	Arterial phase	Venous phase	shape	border	T1WI	T2WI	DWI	Arterialphase	Venousphase	Delayphase

case1	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	hyper	moderate	hyper

case2	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case3	M-R	well	hypo	hetero	moderate	Lob	well	hypo	hyper	hyper	hetero	moderate	mild	hyper

case4	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	hyper	moderate	hyper

case5	M-R-O	well	hypo	hetero	moderate	Lob	well	hypo	hyper	sig. Hyper	hetero	hyper	moderate	hyper

case	M-		hyp	heter	mode		wel	hypo	hyp	sig. Hy	heter	moderate		h

	CT	MRI	DSA

unenhanced	enhancement	unenhanced	Gd-DTPA-enhanced	enhancement

shape	border	density	Arterial phase	Venous phase	shape	border	T1WI	T2WI	DWI	Arterialphase	Venousphase	Delayphase

6	O	well	o	o	rate	M-N	l		er	per	o		mild	yper

case7	M-O	well	hetero, hypo	hetero	moderate	M-N	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case8	S-R	well	hypo	homo	mild	nodule	well	hypo	hyper	hyper	homo	moderate	mild	hyper

case9						M-N	well	hypo	hyper	sig. Hyper	hetero	moderate	mild	hyper

case10						M-N	well	hypo	hyper	sig. Hyper	hetero	mild	mild	hyper

case11						Irr	well	hetero	hyper	hyper	hetero	hetero	hetero	hetero


 	Outlet type

Anti-malarials	Private	Not-for-profit

 	Median price (range) USD	Median price ratio	Median price (range) USD	Median price ratio

AL*	0.94 (0.63-1.25)	1.88	0.75 (0.63-1.00)	1.5

Other forms of ACT**	6.0 (1.88-10.63)	12	2.5 (1.88-3.13)	5

Quinine*	1.0 (0.75-1.25)	1.33	0.75 (0.63-1.13)	1

	Outlet type

Anti-malarials	Private	Not-for-profit

	Median price (range) USD	Median price ratio	Median price (range) USD	Median price ratio

Quinine*	1.0 (0.75-1.25)	1.33	0.75 (0.63-1.13)	1


UUY (Phe)	AAY (Asn)	AAR (Lys)

Leu	0.00	Asn	-0.02	Lys

Ile	0.32	Asp	0.00	Gln

Phe	0.41	Glu	0.23	Glu

Met	0.73	Gln	0.53	Arg

Val	0.75	Lys	1.09	Asn

Tyr	2.17	His	1.11	His

Cys	2.21	Ser	1.20	Asp

Trp	2.37	Pro	1.21	Pro

Thr	2.83	Thr	1.27	Thr

His	3.38	Arg	1.55	Tyr

Pro	3.41	Ala	1.92	Ser

Ala	3.55	Tyr	2.11	Met

Gln	4.18	Gly	2.20	Ala

Ser	4.39	Met	2.50	Trp

Asn	4.76	Cys	2.79	Phe

Arg	4.98	Leu	3.05	Leu

Glu	5.24	Phe	3.06	Gly

Lys	5.37	Val	3.06	Cys

Asp	5.77	Trp	3.06	Val

Gly	6.02	Ile	3.29	Ile


VariableOral morphine equivalents, mg	Pre Group(n = 276)	ERAS Group(n = 96)	p-value

Total Opioid use, Mean (SD)	163.8 (73.2)	111.4 (46.0)	< 0.001*

Intraop Opioid use, Mean (SD)	93.6 (33.8)	73.4 (29.8)	< 0.001*

PACU Opioid use, Mean (SD)	36.7 (30.8)	15.4 (19.3)	< 0.001*

Hospital Floor Opioid use, Mean (SD)	33.4 (44.5)	22.6 (19.3)	0.001*

VariableOral morphine equivalents, mg	Pre Group(n = 276)	ERAS Group(n = 96)	p-value

Total Opioid use, Mean (SD)	163.8 (73.2)	111.4 (46.0)	< 0.001*

Intraop Opioi		73	<

VariableOral morphine equivalents, mg	Pre Group(n = 276)	ERAS Group(n = 96)	p-value

d use, Mean (SD)	93.6 (33.8)	.4 (29.8)	0.001*

PACU Opioid use, Mean (SD)	36.7 (30.8)	15.4 (19.3)	< 0.001*

Hospital Floor Opioid use, Mean (SD)	33.4 (44.5)	22.6 (19.3)	0.001*


Lichen species	Phenolics contentμg of pyrocatechol equivalent	Flavonoid contentμg of rutin equivalent

C. furcata	12.95 ± 1.065	10.55 ± 1.099

L. atra	73.02 ± 1.275	54.77 ± 1.231

L. muralis	43.19 ± 1.085	34.56 ± 1.074

Lichen species

C. furcata

L. atra

L. muralis

Phenolics contentμg of pyrocatechol equivalent	Flavonoid contentμg of rutin equivalent

12.95 ± 1.065	10.55 ± 1.099

73.02 ± 1.275	54.77 ± 1.231

43.19 ± 1.085	34.56 ± 1.074


Disease		Days after inoculation

		8	11	14	17	20

Cercospora leaf spot	Overall accuracy [%]	98.90	89.01	96.58	98.73

	Kappa coefficient	0.99	0.53	0.92	0.98

	Diseased leaf area [%]	0	6.56	7.61	20.92

Powdery mildew	Overall accuracy [%]	94.34	96.79	97.23	90.18

	Kappa coefficient	0.88	0.91	0.95	0.84

	Diseased leaf area [%]	14.40	19.37	41.94	50.04

Sugar beet rust	Overall accuracy [%]					61.70

	Kappa coefficient					0.56

	Diseased leaf area [%]					2.89


Knowledge domain

Overall knowledge

Child health

Postpartum

Newborn care

Injury prevention

Nutrition

Family planning

HIV

Pregnancy

Infection prevention

Malaria


S. No.	Name of the seed	Hot water extraction (%)	Pressurized hot water extraction (%)	Solvent extraction (%)

1.	Syzygium cumini	16.07	49.24	78.14

2.	Citrus sinensis	19.80	74.79	75.65

3.	Mangifera indica	59.54	84.76	65.17

4.	Vitis vinifera	68.87	79.86	83.31

5.	Manilakara zapota	44.72	81.59	81.24

6.	Artocarpus heterophyllus	40.92	87.52	82.68

S. No.	Name of the seed	Hot water extraction (%)	Pressurized hot water extraction (%)	Solvent extraction (%)

2.	Citrus sinensis	19.80	74.79	75.65

3.	Mangifera indica	59.54	84.76	65.17

4.	Vitis vinifera	68.87	79.86	83.31

5.	Manilakara zapota	44.72	81.59	81.24

6.	Artocarpus heterophyllus	40.92	87.52	82.68


		Male

		Heinz 1706	LA716	Periclinal 1

Female	Heinz 1706	Yes	Yes	Yes

LA716	No	Yes	No

Periclinal 1	No	Yes	No

		Male

		Heinz 1706	LA716	Periclinal 1

F	Heinz 1706	Yes	Yes	Yes

LA716	No	Yes	No

Peric	N	Yes	No

		Male

		Heinz 1706	LA716	Periclinal 1

emale	linal 1	o


	U2OS-Cas9	U2OS-Cas9	U2OS-Cas9	HeLa-Cas9	HeLa-Cas9	HeLa-Cas9

No gRNA	EMX1-RNA	EMX1-BNA-5	No gRNA	EMX1-RNA	EMX1-BNA-5

EMX1	0.004	69.181	27.393	<0.003	69.118	25.649


Province	District	Village	No. of larvae

Nangarhar	Behsood	Banaghar, Samarkhel, Saracha	200

Jalalabad	Bagrami	200

Kama	Banajur, Sabirlalay, Sangarsary	200

Kunar	Chawkay	Babur	200

Nurgal	Nurgal	200

Assadabad	Asadabad	200

Province	District	Village	No. of larvae

Nangarhar	Kama	Banajur, Sabirlalay, Sangarsary	200

Kunar	Chawkay	Babur	200

Nurgal	Nurgal	200

Assadabad	Asadabad	200


PCR target	Midguts from mosquitoes fed on gametocyte cultureMean Cp (95% CI)	Midguts with microscopy-confirmed P. falciparum oocystsMean Cp (95% CI)

EHV	24.75(24.68–24.82)	24.14(23.68–24.61)

RPS7	22.85(22.68–23.02)	23.03(22.0–24.07)


	Proton concordant & HiSeq discordant	HiSeq concordant & Proton discordant	All concordant	Both discordant

Total	HiSeq = Proton	All discordant

Average	64	1849	76945	216	202	14

%CV	19.6	55.6	1.24	4.23	5.51	31.6

Common	1	43	66472	80	67	1


Label claim Mg/tablet	Amount added %	Total amount added (mg)	Amount recovered* (mg) ± SD	% Recovery ± SD (n = 3)

Risperidone	50	1	0.99 ± 0.02	99.66 ± 1.79

2	100	2	2.01 ± 0.02	100.21 ± 1.11

	150	3	3.01 ± 0.04	100.31 ± 1.46

Label claim Mg/tablet	Amount added %	Total amount added (mg)	Amount recovered* (mg) ± SD	% Recovery ± SD (n = 3)

Risperi	5	1	0.99 ± 0	9


EcoRI primers	MseI primers

Name	Sequence	Name	Sequence

E1	AAC	M1	CAA

E2	AAG	M2	CAC

E3	ACA	M3	CAG

E4	ACT	M4	CAT

E5	ACC	M5	CTA

E6	ACG	M6	CTC

E7	AGC	M7	CTG

E8	AGG	M8	CTT

EcoRI primers	MseI primers

Name	Sequence	Name	Sequence

E4	ACT	M4	CAT

E5	ACC	M5	CTA

E6	ACG	M6	CTC

E7	AGC	M7	CTG

E8	AGG	M8	CTT


Property	PRD File	FAM File

Identifier	PRD_######, e.g., PRD_000001	FAM_######, e.g., FAM_000001

Name	Molecule name	Family name

Description	• Molecular formula and weight	• List of member PRD identifiers

	• Specific function (class)	• Literature references

	• Structural details (type)

Chemical details	• List of polymer and nonpolymer entities comprising the molecule	• Synonyms for PRD family members collected from various resources including the PDB and primary citations

	• Polymer or subcomponent sequence• Description of how all components in the molecule are linked	• Reference database IDs and links to various resources that provide information about the family members

	 ○ Intra-entity linkages between components in polymer entities	• Family specific annotations

	 ○ Inter-entity linkages between polymer segments and nonpolymer components (for molecules with grouped representation)	 ○ IDs and information about related small molecule crystal structures in the CSD16

		 ○ Corresponding literature references

Biological details	Name of organism producing the molecule (for naturally produced molecules) and source of this information (e.g. from a database, author or literature)	Annotations about structural, functional and mechanistic details for family members, including pharmacological action (where appropriate)


Time of measurement	Before therapy	After therapy (RCI)	Follow-up (RCI)

Outcome variable

PG-13	42	31 (2.66)	23 (4.59)

CAPS—total	50	27 (3.61)	13 (5.81)

CAPS—Intrusion	17	7 (2.66)	5 (3.19)

CAPS—Avoidance	25	14 (2.27)	6 (3.92)

CAPS—Hyper arousal	10	6 (1.23 NS)	2 (2.47)

BDI	22	15 (2.09)	11 (3.28)

Time of measurement	Before therapy	After therapy (RCI)

Outcome variable

PG-13	42	31 (2.66)

CAPS—total	50	27 (3.61)

CAPS—Intrusion	17	7 (2.66)

CAPS—Avoidance	25	14 (2.27)

CAPS—Hyper arousal	10	6 (1.23 NS)

BDI	22	15 (2.09)


Premises	Area (Wales)	Location and Violence Strata

Urban	Town/Fringe	Rural

North	West	South East	High	Low	High	Low	High	Low

Total (N = 30)	4	2	24	8	6	3	10	1	2

Intervention (N = 16)	2	1	13	5	3	1	6	0	1

Control (N = 14)	2	1	11	3	3	2	4	1	1

Premises	Area (Wales)	Location and Violence Strata

Urban	Town/Fringe	Rural

North	West	South East	High	Low	High	Low	High	Low

Intervention (N = 16)	2	1	13	5	3	1	6	0	1

Control (N = 14)	2	1	11	3	3	2	4	1	1


Health problem	Overall	Boy	Girl Significance

Myopia	27.1	25.8	28.5***

Caries	69.6	70.0	69.1***

Obesity	9.5	10.6	8.4***

Dysarthria	2.5	3.0	2.0***

Cryptorchidism	-	2.1	-

Heart murmur	1.5	1.6	1.5

Scoliosis	0.4	0.4	0.4

Atopic dermatitis	0.2	0.2	0.2